42 results on '"Poinsignon V"'
Search Results
2. Factors influencing posaconazole plasmatic concentrations in patients presenting with acute myeloid leukemia
- Author
-
Desplanques, P.-Y., Burlacu, R., Poinsignon, V., Boussion, H., Borget, I., Wyplosz, B., de Botton, S., Billaud, E., Chachaty, E., Gachot, B., Netzer, F., and Micol, J.-B.
- Published
- 2014
- Full Text
- View/download PDF
3. Interaction clozapine et acide valproïque selon le statut tabagique du patient
- Author
-
Habak, L, Garriguet, P., Gaudoneix, M., Ménard, C., Poinsignon, V., and Beauverie, P.
- Published
- 2018
- Full Text
- View/download PDF
4. Pharmacokinetic interaction involving fenofibrate and everolimus
- Author
-
Mir, O., Poinsignon, V., Arnedos, M., Delaloge, S., and Paci, A.
- Published
- 2015
- Full Text
- View/download PDF
5. Résistance ou effets indésirables sous psychotropes : comment prescrire les explorations pharmacogénétiques ?
- Author
-
Poinsignon, V., primary, Verstuyft, C., additional, Thummler, S., additional, and Raymond, S., additional
- Published
- 2019
- Full Text
- View/download PDF
6. The Gaia mission
- Author
-
Prusti, T, De Bruijne, JHJ, Brown, AGA, Vallenari, A, Babusiaux, C, Bailer-Jones, CAL, Bastian, U, Biermann, M, Evans, DW, Eyer, L, Jansen, F, Jordi, C, Klioner, SA, Lammers, U, Lindegren, L, Luri, X, Mignard, F, Milligan, DJ, Panem, C, Poinsignon, V, Pourbaix, D, Randich, S, Sarri, G, Sartoretti, P, Siddiqui, HI, Soubiran, C, Valette, V, Van Leeuwen, F, Walton, NA, Aerts, C, Arenou, F, Cropper, M, Drimmel, R, Høg, E, Katz, D, Lattanzi, MG, O'Mullane, W, Grebel, EK, Holland, AD, Huc, C, Passot, X, Bramante, L, Cacciari, C, Castañeda, J, Chaoul, L, Cheek, N, De Angeli, F, Fabricius, C, Guerra, R, Hernández, J, Jean-Antoine-Piccolo, A, Masana, E, Messineo, R, Mowlavi, N, Nienartowicz, K, Ordóñez-Blanco, D, Panuzzo, P, Portell, J, Richards, PJ, Riello, M, Seabroke, GM, Tanga, P, Thévenin, F, Torra, J, Els, SG, Gracia-Abril, G, Comoretto, G, Garcia-Reinaldos, M, Lock, T, Mercier, E, Altmann, M, Andrae, R, Astraatmadja, TL, Bellas-Velidis, I, Benson, K, Berthier, J, Blomme, R, Busso, G, Carry, B, Cellino, A, Clementini, G, Cowell, S, Creevey, O, Cuypers, J, Davidson, M, De Ridder, J, De Torres, A, Delchambre, L, Dell'Oro, A, Ducourant, C, Frémat, Y, García-Torres, M, Gosset, E, Halbwachs, JL, Hambly, NC, Harrison, DL, Hauser, M, Hestroffer, D, Hodgkin, ST, Huckle, HE, Evans, Dafydd [0000-0002-6685-5998], van Leeuwen, Floor [0000-0003-1781-4441], Walton, Nicholas [0000-0003-3983-8778], Riello, Marco [0000-0002-3134-0935], Harrison, Diana [0000-0001-8687-6588], Hodgkin, Simon [0000-0002-5470-3962], and Apollo - University of Cambridge Repository
- Subjects
proper motions ,parallaxes ,astrometry ,telescopes ,space vehicles: instruments ,Galaxy: structure - Abstract
Gaia is a cornerstone mission in the science programme of the European Space Agency (ESA). The spacecraft construction was approved in 2006, following a study in which the original interferometric concept was changed to a direct-imaging approach. Both the spacecraft and the payload were built by European industry. The involvement of the scientific community focusses on data processing for which the international Gaia Data Processing and Analysis Consortium (DPAC) was selected in 2007. Gaia was launched on 19 December 2013 and arrived at its operating point, the second Lagrange point of the Sun-Earth-Moon system, a few weeks later. The commissioning of the spacecraft and payload was completed on 19 July 2014. The nominal five-year mission started with four weeks of special, ecliptic-pole scanning and subsequently transferred into full-sky scanning mode. We recall the scientific goals of Gaia and give a description of the as-built spacecraft that is currently (mid-2016) being operated to achieve these goals. We pay special attention to the payload module, the performance of which is closely related to the scientific performance of the mission. We provide a summary of the commissioning activities and findings, followed by a description of the routine operational mode. We summarise scientific performance estimates on the basis of in-orbit operations. Several intermediate Gaia data releases are planned and the data can be retrieved from the Gaia Archive, which is available through the Gaia home page at http://www.cosmos.esa.int/gaia.
- Published
- 2018
- Full Text
- View/download PDF
7. Serum assessment of non-adherence to adjuvant endocrine therapy (ET) among premenopausal patients in the prospective multicenter CANTO cohort
- Author
-
Pistilli, B., primary, Paci, A., additional, Michiels, S., additional, Ferreira, A., additional, Poinsignon, V., additional, Cottu, P.H., additional, Lerebours, F., additional, Coutant, C., additional, Lesur, A., additional, Tredan, O., additional, Soulie, P., additional, Vanlemmens, L., additional, Jouannaud, C., additional, Levy, C., additional, Everhard, S., additional, Arveux, P., additional, Partridge, A.H., additional, Delaloge, S., additional, André, F., additional, and Vaz-Luis, I., additional
- Published
- 2018
- Full Text
- View/download PDF
8. The Gaia mission
- Author
-
Prusti, T. De Bruijne, J.H.J. Brown, A.G.A. Vallenari, A. Babusiaux, C. Bailer-Jones, C.A.L. Bastian, U. Biermann, M. Evans, D.W. Eyer, L. Jansen, F. Jordi, C. Klioner, S.A. Lammers, U. Lindegren, L. Luri, X. Mignard, F. Milligan, D.J. Panem, C. Poinsignon, V. Pourbaix, D. Randich, S. Sarri, G. Sartoretti, P. Siddiqui, H.I. Soubiran, C. Valette, V. Van Leeuwen, F. Walton, N.A. Aerts, C. Arenou, F. Cropper, M. Drimmel, R. Høg, E. Katz, D. Lattanzi, M.G. O'Mullane, W. Grebel, E.K. Holland, A.D. Huc, C. Passot, X. Bramante, L. Cacciari, C. Castañeda, J. Chaoul, L. Cheek, N. De Angeli, F. Fabricius, C. Guerra, R. Hernández, J. Jean-Antoine-Piccolo, A. Masana, E. Messineo, R. Mowlavi, N. Nienartowicz, K. Ordóñez-Blanco, D. Panuzzo, P. Portell, J. Richards, P.J. Riello, M. Seabroke, G.M. Tanga, P. Thévenin, F. Torra, J. Els, S.G. Gracia-Abril, G. Comoretto, G. Garcia-Reinaldos, M. Lock, T. Mercier, E. Altmann, M. Andrae, R. Astraatmadja, T.L. Bellas-Velidis, I. Benson, K. Berthier, J. Blomme, R. Busso, G. Carry, B. Cellino, A. Clementini, G. Cowell, S. Creevey, O. Cuypers, J. Davidson, M. De Ridder, J. De Torres, A. Delchambre, L. Dell'Oro, A. Ducourant, C. Frémat, Y. García-Torres, M. Gosset, E. Halbwachs, J.-L. Hambly, N.C. Harrison, D.L. Hauser, M. Hestroffer, D. Hodgkin, S.T. Huckle, H.E. Hutton, A. Jasniewicz, G. Jordan, S. Kontizas, M. Korn, A.J. Lanzafame, A.C. Manteiga, M. Moitinho, A. Muinonen, K. Osinde, J. Pancino, E. Pauwels, T. Petit, J.-M. Recio-Blanco, A. Robin, A.C. Sarro, L.M. Siopis, C. Smith, M. Smith, K.W. Sozzetti, A. Thuillot, W. Van Reeven, W. Viala, Y. Abbas, U. Abreu Aramburu, A. Accart, S. Aguado, J.J. Allan, P.M. Allasia, W. Altavilla, G. Álvarez, M.A. Alves, J. Anderson, R.I. Andrei, A.H. Anglada Varela, E. Antiche, E. Antoja, T. Antón, S. Arcay, B. Atzei, A. Ayache, L. Bach, N. Baker, S.G. Balaguer-Núñez, L. Barache, C. Barata, C. Barbier, A. Barblan, F. Baroni, M. Barrado Y Navascués, D. Barros, M. Barstow, M.A. Becciani, U. Bellazzini, M. Bellei, G. Bello García, A. Belokurov, V. Bendjoya, P. Berihuete, A. Bianchi, L. Bienaymé, O. Billebaud, F. Blagorodnova, N. Blanco-Cuaresma, S. Boch, T. Bombrun, A. Borrachero, R. Bouquillon, S. Bourda, G. Bouy, H. Bragaglia, A. Breddels, M.A. Brouillet, N. Brüsemeister, T. Bucciarelli, B. Budnik, F. Burgess, P. Burgon, R. Burlacu, A. Busonero, D. Buzzi, R. Caffau, E. Cambras, J. Campbell, H. Cancelliere, R. Cantat-Gaudin, T. Carlucci, T. Carrasco, J.M. Castellani, M. Charlot, P. Charnas, J. Charvet, P. Chassat, F. Chiavassa, A. Clotet, M. Cocozza, G. Collins, R.S. Collins, P. Costigan, G. Crifo, F. Cross, N.J.G. Crosta, M. Crowley, C. Dafonte, C. Damerdji, Y. Dapergolas, A. David, P. David, M. De Cat, P. De Felice, F. De Laverny, P. De Luise, F. De March, R. De Martino, D. De Souza, R. Debosscher, J. Del Pozo, E. Delbo, M. Delgado, A. Delgado, H.E. Di Marco, F. Di Matteo, P. Diakite, S. Distefano, E. Dolding, C. Dos Anjos, S. Drazinos, P. Durán, J. Dzigan, Y. Ecale, E. Edvardsson, B. Enke, H. Erdmann, M. Escolar, D. Espina, M. Evans, N.W. Eynard Bontemps, G. Fabre, C. Fabrizio, M. Faigler, S. Falcão, A.J. Farràs Casas, M. Faye, F. Federici, L. Fedorets, G. Fernández-Hernández, J. Fernique, P. Fienga, A. Figueras, F. Filippi, F. Findeisen, K. Fonti, A. Fouesneau, M. Fraile, E. Fraser, M. Fuchs, J. Furnell, R. Gai, M. Galleti, S. Galluccio, L. Garabato, D. García-Sedano, F. Garé, P. Garofalo, A. Garralda, N. Gavras, P. Gerssen, J. Geyer, R. Gilmore, G. Girona, S. Giuffrida, G. Gomes, M. González-Marcos, A. González-Núñez, J. González-Vidal, J.J. Granvik, M. Guerrier, A. Guillout, P. Guiraud, J. Gúrpide, A. Gutiérrez-Sánchez, R. Guy, L.P. Haigron, R. Hatzidimitriou, D. Haywood, M. Heiter, U. Helmi, A. Hobbs, D. Hofmann, W. Holl, B. Holland, G. Hunt, J.A.S. Hypki, A. Icardi, V. Irwin, M. Jevardat De Fombelle, G. Jofré, P. Jonker, P.G. Jorissen, A. Julbe, F. Karampelas, A. Kochoska, A. Kohley, R. Kolenberg, K. Kontizas, E. Koposov, S.E. Kordopatis, G. Koubsky, P. Kowalczyk, A. Krone-Martins, A. Kudryashova, M. Kull, I. Bachchan, R.K. Lacoste-Seris, F. Lanza, A.F. Lavigne, J.-B. Le Poncin-Lafitte, C. Lebreton, Y. Lebzelter, T. Leccia, S. Leclerc, N. Lecoeur-Taibi, I. Lemaitre, V. Lenhardt, H. Leroux, F. Liao, S. Licata, E. Lindstrøm, H.E.P. Lister, T.A. Livanou, E. Lobel, A. Löffler, W. López, M. Lopez-Lozano, A. Lorenz, D. Loureiro, T. MacDonald, I. Magalhães Fernandes, T. Managau, S. Mann, R.G. Mantelet, G. Marchal, O. Marchant, J.M. Marconi, M. Marie, J. Marinoni, S. Marrese, P.M. Marschalkó, G. Marshall, D.J. Martín-Fleitas, J.M. Martino, M. Mary, N. Matijevič, G. Mazeh, T. McMillan, P.J. Messina, S. Mestre, A. Michalik, D. Millar, N.R. Miranda, B.M.H. Molina, D. Molinaro, R. Molinaro, M. Molnár, L. Moniez, M. Montegriffo, P. Monteiro, D. Mor, R. Mora, A. Morbidelli, R. Morel, T. Morgenthaler, S. Morley, T. Morris, D. Mulone, A.F. Muraveva, T. Musella, I. Narbonne, J. Nelemans, G. Nicastro, L. Noval, L. Ordénovic, C. Ordieres-Meré, J. Osborne, P. Pagani, C. Pagano, I. Pailler, F. Palacin, H. Palaversa, L. Parsons, P. Paulsen, T. Pecoraro, M. Pedrosa, R. Pentikäinen, H. Pereira, J. Pichon, B. Piersimoni, A.M. Pineau, F.-X. Plachy, E. Plum, G. Poujoulet, E. Prša, A. Pulone, L. Ragaini, S. Rago, S. Rambaux, N. Ramos-Lerate, M. Ranalli, P. Rauw, G. Read, A. Regibo, S. Renk, F. Reylé, C. Ribeiro, R.A. Rimoldini, L. Ripepi, V. Riva, A. Rixon, G. Roelens, M. Romero-Gómez, M. Rowell, N. Royer, F. Rudolph, A. Ruiz-Dern, L. Sadowski, G. Sagristà Sellés, T. Sahlmann, J. Salgado, J. Salguero, E. Sarasso, M. Savietto, H. Schnorhk, A. Schultheis, M. Sciacca, E. Segol, M. Segovia, J.C. Segransan, D. Serpell, E. Shih, I.-C. Smareglia, R. Smart, R.L. Smith, C. Solano, E. Solitro, F. Sordo, R. Soria Nieto, S. Souchay, J. Spagna, A. Spoto, F. Stampa, U. Steele, I.A. Steidelmüller, H. Stephenson, C.A. Stoev, H. Suess, F.F. Süveges, M. Surdej, J. Szabados, L. Szegedi-Elek, E. Tapiador, D. Taris, F. Tauran, G. Taylor, M.B. Teixeira, R. Terrett, D. Tingley, B. Trager, S.C. Turon, C. Ulla, A. Utrilla, E. Valentini, G. Van Elteren, A. Van Hemelryck, E. Van Leeuwen, M. Varadi, M. Vecchiato, A. Veljanoski, J. Via, T. Vicente, D. Vogt, S. Voss, H. Votruba, V. Voutsinas, S. Walmsley, G. Weiler, M. Weingrill, K. Werner, D. Wevers, T. Whitehead, G. Wyrzykowski, Ł. Yoldas, A. Žerjal, M. Zucker, S. Zurbach, C. Zwitter, T. Alecu, A. Allen, M. Allende Prieto, C. Amorim, A. Anglada-Escudé, G. Arsenijevic, V. Azaz, S. Balm, P. Beck, M. Bernstein, H.-H. Bigot, L. Bijaoui, A. Blasco, C. Bonfigli, M. Bono, G. Boudreault, S. Bressan, A. Brown, S. Brunet, P.-M. Bunclark, P. Buonanno, R. Butkevich, A.G. Carret, C. Carrion, C. Chemin, L. Chéreau, F. Corcione, L. Darmigny, E. De Boer, K.S. De Teodoro, P. De Zeeuw, P.T. Delle Luche, C. Domingues, C.D. Dubath, P. Fodor, F. Frézouls, B. Fries, A. Fustes, D. Fyfe, D. Gallardo, E. Gallegos, J. Gardiol, D. Gebran, M. Gomboc, A. Gómez, A. Grux, E. Gueguen, A. Heyrovsky, A. Hoar, J. Iannicola, G. Isasi Parache, Y. Janotto, A.-M. Joliet, E. Jonckheere, A. Keil, R. Kim, D.-W. Klagyivik, P. Klar, J. Knude, J. Kochukhov, O. Kolka, I. Kos, J. Kutka, A. Lainey, V. Lebouquin, D. Liu, C. Loreggia, D. Makarov, V.V. Marseille, M.G. Martayan, C. Martinez-Rubi, O. Massart, B. Meynadier, F. Mignot, S. Munari, U. Nguyen, A.-T. Nordlander, T. Ocvirk, P. O'Flaherty, K.S. Olias Sanz, A. Ortiz, P. Osorio, J. Oszkiewicz, D. Ouzounis, A. Palmer, M. Park, P. Pasquato, E. Peltzer, C. Peralta, J. Péturaud, F. Pieniluoma, T. Pigozzi, E. Poels, J. Prat, G. Prod'homme, T. Raison, F. Rebordao, J.M. Risquez, D. Rocca-Volmerange, B. Rosen, S. Ruiz-Fuertes, M.I. Russo, F. Sembay, S. Serraller Vizcaino, I. Short, A. Siebert, A. Silva, H. Sinachopoulos, D. Slezak, E. Soffel, M. Sosnowska, D. Straižys, V. Ter Linden, M. Terrell, D. Theil, S. Tiede, C. Troisi, L. Tsalmantza, P. Tur, D. Vaccari, M. Vachier, F. Valles, P. Van Hamme, W. Veltz, L. Virtanen, J. Wallut, J.-M. Wichmann, R. Wilkinson, M.I. Ziaeepour, H. Zschocke, S.
- Subjects
instruments [space vehicles] ,proper motions ,parallaxes ,astrometry ,telescopes ,structure [Galaxy] - Abstract
Gaia is a cornerstone mission in the science programme of the European Space Agency (ESA). The spacecraft construction was approved in 2006, following a study in which the original interferometric concept was changed to a direct-imaging approach. Both the spacecraft and the payload were built by European industry. The involvement of the scientific community focusses on data processing for which the international Gaia Data Processing and Analysis Consortium (DPAC) was selected in 2007. Gaia was launched on 19 December 2013 and arrived at its operating point, the second Lagrange point of the Sun-Earth-Moon system, a few weeks later. The commissioning of the spacecraft and payload was completed on 19 July 2014. The nominal five-year mission started with four weeks of special, ecliptic-pole scanning and subsequently transferred into full-sky scanning mode. We recall the scientific goals of Gaia and give a description of the as-built spacecraft that is currently (mid-2016) being operated to achieve these goals. We pay special attention to the payload module, the performance of which is closely related to the scientific performance of the mission. We provide a summary of the commissioning activities and findings, followed by a description of the routine operational mode. We summarise scientific performance estimates on the basis of in-orbit operations. Several intermediate Gaia data releases are planned and the data can be retrieved from the Gaia Archive, which is available through the Gaia home page.http://www.cosmos.esa.int/gaia
- Published
- 2016
9. The Gaia mission
- Author
-
Prusti, T., de Bruijne, J. H. J., Brown, A. G. A., Vallenari, A., Babusiaux, C., Bailer-Jones, C. A. L., Bastian, U., Biermann, M., Evans, D. W., Eyer, L., Jansen, F., Jordi, C., Klioner, S. A., Lammers, U., Lindegren, L., Luri, X., Mignard, F., Milligan, D. J., Panem, C., Poinsignon, V., Pourbaix, D., Randich, S., Sarri, G., Sartoretti, P., Siddiqui, H. I., Soubiran, C., Valette, V., van Leeuwen, F., Walton, N. A., Aerts, C., Arenou, F., Cropper, M., Drimmel, R., Hog, E., Katz, D., Lattanzi, M. G., O'Mullane, W., Grebel, E. K., Holland, A. D., Huc, C., Passot, X., Bramante, L., Cacciari, C., Castaneda, J., Chaoul, L., Cheek, N., De Angeli, F., Fabricius, C., Guerra, R., and Tingley, B.
- Subjects
instruments [space vehicles] ,STANDARD STARS ,telescopes ,CA-II TRIPLET ,CCD RADIATION-DAMAGE ,ASTROMETRIC SOLUTION ,COVARIANCE EXPANSION MODEL ,SOLAR-SYSTEM ,GRAVITATIONAL-FIELD ,proper motions ,GENERAL-RELATIVISTIC MODEL ,parallaxes ,astrometry ,structure [Galaxy] ,FGK BENCHMARK STARS ,ERROR CHARACTERIZATION - Abstract
Gaia is a cornerstone mission in the science programme of the European Space Agency (ESA). The spacecraft construction was approved in 2006, following a study in which the original interferometric concept was changed to a direct-imaging approach. Both the spacecraft and the payload were built by European industry. The involvement of the scientific community focusses on data processing for which the international Gaia Data Processing and Analysis Consortium (DPAC) was selected in 2007. Gaia was launched on 19 December 2013 and arrived at its operating point, the second Lagrange point of the Sun-Earth-Moon system, a few weeks later. The commissioning of the spacecraft and payload was completed on 19 July 2014. The nominal five-year mission started with four weeks of special, ecliptic-pole scanning and subsequently transferred into full-sky scanning mode. We recall the scientific goals of Gaia and give a description of the as-built spacecraft that is currently (mid-2016) being operated to achieve these goals. We pay special attention to the payload module, the performance of which is closely related to the scientific performance of the mission. We provide a summary of the commissioning activities and findings, followed by a description of the routine operational mode. We summarise scientific performance estimates on the basis of in-orbit operations. Several intermediate Gaia data releases are planned and the data can be retrieved from the Gaia Archive, which is available through the Gaia home page.
- Published
- 2016
10. Importance of therapeutic drug monitoring associated with pharmacogenetics: case reports in a French psychiatric hospital
- Author
-
Poinsignon, V., primary, Poinsat, T., additional, Raymond, S., additional, Astier, M., additional, Verstuyft, C., additional, Paci, A., additional, Gaudoneix, M., additional, and Beauverie, P., additional
- Published
- 2016
- Full Text
- View/download PDF
11. Prescription analysis in women of childbearing age hospitalised in psychiatry: teratogenic risk
- Author
-
Poinsat, T., primary, Lachuer, C., additional, Poinsignon, V., additional, Gaudoneix, M., additional, and Beauverie, P., additional
- Published
- 2016
- Full Text
- View/download PDF
12. Impact of risk minimization measures associated with valproate and related substances in a French psychiatric hospital
- Author
-
Lachuer, C., primary, Poinsat, T., additional, Poinsignon, V., additional, Gaudoneix, M., additional, and Beauverie, P., additional
- Published
- 2016
- Full Text
- View/download PDF
13. 185O_PR - Serum assessment of non-adherence to adjuvant endocrine therapy (ET) among premenopausal patients in the prospective multicenter CANTO cohort
- Author
-
Pistilli, B., Paci, A., Michiels, S., Ferreira, A., Poinsignon, V., Cottu, P.H., Lerebours, F., Coutant, C., Lesur, A., Tredan, O., Soulie, P., Vanlemmens, L., Jouannaud, C., Levy, C., Everhard, S., Arveux, P., Partridge, A.H., Delaloge, S., André, F., and Vaz-Luis, I.
- Published
- 2018
- Full Text
- View/download PDF
14. P.3.f.020 - Prescription analysis in women of childbearing age hospitalised in psychiatry: teratogenic risk
- Author
-
Poinsat, T., Lachuer, C., Poinsignon, V., Gaudoneix, M., and Beauverie, P.
- Published
- 2016
- Full Text
- View/download PDF
15. P.3.f.017 - Importance of therapeutic drug monitoring associated with pharmacogenetics: case reports in a French psychiatric hospital
- Author
-
Poinsignon, V., Poinsat, T., Raymond, S., Astier, M., Verstuyft, C., Paci, A., Gaudoneix, M., and Beauverie, P.
- Published
- 2016
- Full Text
- View/download PDF
16. P.2.f.019 - Impact of risk minimization measures associated with valproate and related substances in a French psychiatric hospital
- Author
-
Lachuer, C., Poinsat, T., Poinsignon, V., Gaudoneix, M., and Beauverie, P.
- Published
- 2016
- Full Text
- View/download PDF
17. Facteurs influençant les résultats du dosage de posaconazole chez les patients atteints de leucémie aiguë myéloïde
- Author
-
Micol, J.-B., primary, Desplanques, P.-Y., additional, Burlacu, R., additional, Poinsignon, V., additional, Boussion, H., additional, Chachaty, E., additional, Borget, I., additional, Billaud, E., additional, Gachot, B., additional, and Netzer, F., additional
- Published
- 2013
- Full Text
- View/download PDF
18. The Gaia mission
- Author
-
Belokurov, V., Troisi, L., Zurbach, C., Krone-Martins, A., Blagorodnova, N., Prusti, T., Guerra, R., Tapiador, D., Thuillot, W., Aerts, C., De Angeli, F., Hobbs, D., Martino, M., Ayache, L., Virtanen, J., Fonti, A., Nienartowicz, K., Pieniluoma, T., Molinaro, M., Mora, A., Irwin, M., Baker, S., Jordi, C., Abbas, U., Olias Sanz, A., Gai, M., Masana, E., Garofalo, A., Cropper, M., Gómez, M., Høg, E., Bendjoya, P., Ulla, A., Barros, M., Montegriffo, P., Vecchiato, A., Gebran, M., Fustes, D., Bigot, L., Helmi, A., Anderson, R., Seabroke, M., Di Matteo, P., Lanza, F., Fraile, E., Ruiz-Dern, L., Barbier, A., Segransan, D., Rauw, G., David, P., Burgess, P., Ribeiro, R., Van Leeuwen, F., Smareglia, R., Kutka, A., Gavras, P., Salgado, J., Gosset, E., Arsenijevic, V., Pourbaix, D., Hernández, J., Hypki, A., De Laverny, P., Gallegos, J., Altavilla, G., Molina, D., Barrado Y Navascués, D., Marchal, O., Sagristà Sellés, T., Milligan, J., Sciacca, E., Bello García, A., Bombrun, A., Vallenari, A., Drazinos, P., Barata, C., Karampelas, A., Anglada Varela, E., Spagna, A., Creevey, O., David, M., Munari, U., Arcay, B., Isasi Parache, Y., Serraller Vizcaino, I., Schultheis, M., Brunet, P., Prat, G., Andrae, R., Ripepi, V., Burgon, R., Pagano, I., Lopez-Lozano, A., Gracia-Abril, G., Barache, C., Bouy, H., Blasco, C., Gilmore, G., Andrei, H., Iannicola, G., Tsalmantza, P., Wallut, J.-M., Bragaglia, A., Brown, S., Amorim, A., Roelens, M., Blomme, R., Martinez-Rubi, O., Taris, F., Balaguer-Núñez, L., Pasquato, E., Frézouls, B., Janotto, M., Vicente, D., Hambly, C., Galluccio, L., Holland, G., Van Reeven, W., Charvet, P., Palacin, H., Peltzer, C., Blanco-Cuaresma, S., De Bruijne, H., Garé, P., Rimoldini, L., Mowlavi, N., Brüsemeister, T., Soria Nieto, S., Korn, J., Zschocke, S., Holl, B., Palaversa, L., De Luise, F., Luri, X., Solano, E., Leroux, F., Stampa, U., Meynadier, F., Collins, S., Liu, C., Bourda, G., Mary, N., García-Torres, M., Comoretto, G., Bellei, G., Short, A., Arenou, F., Petit, J.-M., Ramos-Lerate, M., Chéreau, F., Carry, B., Gomes, M., Ortiz, P., Ranalli, P., Marinoni, S., Boch, T., Michalik, D., Bachchan, R., Delgado, H., Jasniewicz, G., Sarro, L., Budnik, F., Koubsky, P., Faye, F., Kontizas, M., Marchant, J., Vogt, S., Grux, E., Crosta, M., Klar, J., Plum, G., Kudryashova, M., Lister, A., Risquez, D., Kochukhov, O., Robin, C., Werner, D., Carlucci, T., Mercier, E., Holland, D., Trager, S., Allen, M., Pedrosa, R., Pecoraro, M., Charlot, P., Brown, A., Joliet, E., Weiler, M., Gueguen, A., Lanza, C., Ordénovic, C., García-Sedano, F., Randich, S., Rowell, N., Marschalkó, G., Yoldas, A., Spoto, F., Anglada-Escudé, G., Hodgkin, S., Carrion, Claire, Cantat-Gaudin, T., Fouesneau, M., Rambaux, N., Stephenson, C., Geyer, R., Campbell, H., Babusiaux, C., Altmann, M., Valentini, G., Wilkinson, M., Narbonne, J., Suess, F., Royer, F., Gallardo, E., De Felice, F., Voss, H., Monteiro, D., Pichon, B., Diakite, S., Martino, D., Evans, W., Barstow, M., Löffler, W., Fabricius, C., Park, P., Pailler, F., Damerdji, Y., Theil, S., Palmer, M., Burlacu, A., Bach, N., Lock, T., Walton, A., Silva, H., Astraatmadja, L., Rudolph, A., Cellino, A., Gerssen, J., O’Mullane, W., Bianchi, L., Del Pozo, E., Fries, A., Mestre, A., Girona, S., Teixeira, R., Filippi, F., Pauwels, T., Siopis, C., Siebert, A., Schnorhk, A., Managau, S., Siddiqui, H., Osborne, P., Steele, A., Kordopatis, G., Carrasco, J., Jonckheere, A., Plachy, E., Busso, G., Castañeda, J., Makarov, V., Sarri, G., Hestroffer, D., Domingues, D., Galleti, S., Tur, D., González-Núñez, J., Segol, M., De Teodoro, P., Bucciarelli, B., Varadi, M., Soffel, M., Fedorets, G., Terrett, D., Moniez, M., Marconi, M., Via, Y., Macdonald, I., Halbwachs, J., Allende Prieto, C., Muinonen, K., Eynard Bontemps, G., Walmsley, G., Abreu Aramburu, A., Gúrpide, A., Terrell, D., Loureiro, T., Panem, C., Guerrier, A., Paulsen, T., Delle Luche, C., Dubath, P., Antiche, E., Prša, A., Haywood, M., Mor, R., Prod’Homme, T., Licata, E., Guillout, P., De Ridder, J., Eyer, L., Hatzidimitriou, D., Péturaud, F., Borrachero, R., Souchay, J., Debosscher, J., Granvik, M., Recio-Blanco, A., Parsons, P., Bellazzini, M., Durán, J., Knude, J., Lobel, A., Nicastro, L., Mignard, F., Buzzi, R., Slezak, E., Shih, C., Riello, M., Kim, W., Morley, T., Fienga, A., Votruba, V., Gomboc, A., Dell’Oro, A., Tiede, C., Jevardat De Fombelle, G., Nelemans, G., Jofré, P., Nguyen, A., Žerjal, M., Szabados, L., Kolenberg, K., Kos, J., Martayan, C., Riva, A., Süveges, M., Zucker, S., Renk, F., Hoar, J., Smart, R., Crowley, C., Bono, G., Hutton, A., Le Poncin-Lafitte, C., Segovia, J., Els, S., Solitro, F., Miranda, H., Bernstein, H., Mann, R., Frémat, Y., Wevers, T., Heiter, U., Matijevič, G., Berthier, J., Russo, F., Giuffrida, G., Millar, R., Balm, P., Delbo, M., Lindegren, L., Keil, R., Mulone, F., Weingrill, K., Chassat, F., Falcão, J., Farràs Casas, M., Huckle, H., Livanou, E., González-Vidal, J., Nordlander, T., Van Hemelryck, E., Szegedi-Elek, E., Garralda, N., Van Hamme, W., Bijaoui, A., Sinachopoulos, D., Reylé, C., Sarasso, M., Martín-Fleitas, J., Raison, F., Molinaro, R., Wichmann, R., Rixon, G., Rocca-Volmerange, B., Pineau, F., Piersimoni, M., Torra, J., Soubiran, C., Lainey, V., Kull, I., Fodor, F., Erdmann, M., Berihuete, A., Collins, P., Enke, H., Pancino, E., Dafonte, C., Kohley, R., Passot, X., Ducourant, C., Lavigne, J., Dapergolas, A., Bressan, A., Richards, J., Allan, P., Loreggia, D., Distefano, E., Sosnowska, D., Valles, P., Ziaeepour, H., Marseille, M., López, M., De Cat, P., Allasia, W., Aguado, J., Dolding, C., Poels, J., Espina, M., Álvarez, M., Lorenz, D., Utrilla, E., Fabrizio, M., Chaoul, L., Bastian, U., Benson, K., Biermann, M., Antoja, T., Pulone, L., Poinsignon, V., Katz, D., Hofmann, W., Findeisen, K., Via, T., Faigler, S., Rebordao, J., Huc, C., Barblan, F., Sadowski, G., Taylor, M., Sordo, R., Lebouquin, D., Read, A., Butkevich, A., Van Elteren, A., Manteiga, M., Hauser, M., Jonker, P., Voutsinas, S., Morbidelli, R., Fuchs, J., Bouquillon, S., Molnár, L., Gutiérrez-Sánchez, R., Accart, S., Vachier, F., Cocozza, G., Marshall, J., Sahlmann, J., Kochoska, A., De March, R., Portell, J., Tanga, P., Edvardsson, B., Osorio, J., Antón, S., Pigozzi, E., Alves, J., Kowalczyk, A., Chiavassa, A., Savietto, H., Sembay, S., Veljanoski, J., Klagyivik, P., Tur, C., Ecale, E., Bienaymé, O., Dos Anjos, S., Leccia, S., Messineo, R., Serpell, E., Guy, L., Harrison, L., Bailer-Jones, L., Cheek, N., Dzigan, Y., Ordieres-Meré, J., Tingley, B., Poujoulet, E., Cowell, S., Ragaini, S., De Torres, A., Marie, J., Baroni, M., Lenhardt, H., Osinde, J., Lemaitre, V., Pereira, J., Thévenin, F., Di Marco, F., Ruiz-Fuertes, M., Klioner, S., Darmigny, E., Ouzounis, A., Julbe, F., Busonero, D., Grebel, E., Jordan, S., Cacciari, C., Clotet, M., Stoev, H., Vaccari, M., Moitinho, A., Rago, S., Fernique, P., Ordóñez-Blanco, D., Veltz, L., Liao, S., Escolar, D., Messina, S., Drimmel, R., Lindstrøm, H., Heyrovsky, A., Guiraud, J., Breddels, M., Garabato, D., Rosen, S., Mcmillan, J., Straižys, V., Gardiol, D., Lebreton, Y., Mazeh, T., Beck, M., Bunclark, P., Peralta, J., Ter Linden, M., Mantelet, G., Morel, T., Furnell, R., Sartoretti, P., Jean-Antoine-Piccolo, A., Van Leeuwen, M., Steidelmüller, H., Azaz, S., Pentikäinen, H., Kolka, I., Wyrzykowski, Ł., Clementini, G., Charnas, J., Alecu, A., Kontizas, E., Figueras, F., Fyfe, D., Crifo, F., Jansen, F., Delgado, A., Costigan, G., Fernández-Hernández, J., Koposov, S., Valette, V., Surdej, J., Massart, B., Castellani, M., Morgenthaler, S., Regibo, S., Delchambre, L., Fraser, M., Cancelliere, R., Boudreault, S., Marrese, P., Chemin, L., Lattanzi, M., Bramante, L., Gómez, A., Bellas-Velidis, I., Leclerc, N., Federici, L., Cuypers, J., Hunt, S., Cambras, J., Brouillet, N., Icardi, V., Tauran, G., Cross, J., Atzei, A., Corcione, L., De Zeeuw, P., Lebzelter, T., Lammers, U., Ocvirk, P., Smith, M., Magalhães Fernandes, T., Carret, C., Smith, C., Sozzetti, A., Billebaud, F., De Souza, R., De Boer, S., Zwitter, T., Lacoste-Seris, F., Muraveva, T., Jorissen, A., Pagani, C., Smith, W., Musella, I., Haigron, R., Caffau, E., Panuzzo, P., Oszkiewicz, D., Garcia-Reinaldos, M., Noval, L., González-Marcos, A., Salguero, E., Lecoeur-Taibi, I., Becciani, U., Whitehead, G., Bonfigli, M., Fabre, C., Mignot, S., O’Flaherty, S., Buonanno, R., Morris, D., Carrion, C., Collaboration, Gaia, De Bruijne, J.H.J., European Space Research and Technology Centre (ESTEC), Agence Spatiale Européenne = European Space Agency (ESA), Galaxies, Etoiles, Physique, Instrumentation (GEPI), Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS), Zentrum für astronomie, Universität Heidelberg [Heidelberg] = Heidelberg University, Department of nuclear medicine, Haukeland University Hospital, University of Bergen (UiB)-University of Bergen (UiB), Department of Clinical Medicine, University of Bergen (UiB), Centre for Research in Earth and Space Science [Toronto] (CRESS), York University [Toronto], Geneva Observatory, Université de Genève = University of Geneva (UNIGE), Joseph Louis LAGRANGE (LAGRANGE), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de la Côte d'Azur, COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Jennifer Milligan, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Astrophysique de Bordeaux [Pessac] (LAB), Université de Bordeaux (UB)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS), Centre National d'Études Spatiales [Toulouse] (CNES), Institute of Astronomy [Leuven], Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Astronomische Rechen-Institut [Heidelberg] (ARI), Zentrum für Astronomie der Universität Heidelberg (ZAH), Universität Heidelberg [Heidelberg] = Heidelberg University-Universität Heidelberg [Heidelberg] = Heidelberg University, University of California [San Diego] (UC San Diego), University of California (UC), INAF - Osservatorio Astronomico di Bologna (OABO), Istituto Nazionale di Astrofisica (INAF), Institut de Ciencies del Cosmos (ICCUB), Universitat de Barcelona (UB), European Space Astronomy Centre (ESAC), Systèmes de Référence Temps Espace (SYRTE), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de Paris, Mullard Space Science Laboratory (MSSL), University College of London [London] (UCL), Institut de Mécanique Céleste et de Calcul des Ephémérides (IMCCE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université de Lille-Centre National de la Recherche Scientifique (CNRS), Royal Observatory of Belgium [Brussels] (ROB), Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO), Institut d'astrophysique spatiale (IAS), Université Paris-Sud - Paris 11 (UP11)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Centre National d’Études Spatiales [Paris] (CNES), Université de Picardie Jules Verne (UPJV), University of Edinburgh, Laboratório de Ictiologia e Pesca, Universidade Federal de Rondônia [Brésil] (UNIR), Institute of Astronomy [Cambridge], University of Cambridge [UK] (CAM), Laboratoire Univers et Particules de Montpellier (LUPM), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Université d'Athènes (UOA), SIM/IDL Faculdade de Ciências da Universidade de Lisboa (FCUL), University of Lisboa, Univers, Transport, Interfaces, Nanostructures, Atmosphère et environnement, Molécules (UMR 6213) (UTINAM), Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Florida State University [Tallahassee] (FSU), Department of Computer Science, University of York [York, UK], INAF - Osservatorio Astrofisico di Torino (OATo), Universidad de Murcia, EURIX Software Innovators, INTA (INTA), INTA, CESAM, Universidade de Aveiro, South Iceland Research Centre, University of Iceland [Reykjavik], United States Geological Survey [Reston] (USGS), Récepteurs et Canaux Ioniques Membranaires (RCIM), Université d'Angers (UA)-Institut National de la Recherche Agronomique (INRA), Department of Medicine, Icahn School of Medicine at Mount Sinai [New York] (MSSM), Institute of Environmental Assessment and Water Research (IDAEA), Consejo Superior de Investigaciones Científicas [Madrid] (CSIC), Thales Services, THALES [France], Institut de Planétologie et d'Astrophysique de Grenoble (IPAG), Institut national des sciences de l'Univers (INSU - CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Observatoire des Sciences de l'Univers de Grenoble (OSUG ), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut national des sciences de l'Univers (INSU - CNRS)-Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Department of Physics and Astronomy [Leicester], University of Leicester, COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), Observatoire astronomique de Strasbourg (ObAS), Université de Strasbourg (UNISTRA)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS), Observatoire aquitain des sciences de l'univers (OASU), Université Sciences et Technologies - Bordeaux 1 (UB)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS), Observatoire Astronomique de l'Université de Genève (ObsGE), Centro de Astrobiologia [Madrid] (CAB), Instituto Nacional de Técnica Aeroespacial (INTA)-Consejo Superior de Investigaciones Científicas [Madrid] (CSIC), School of Physical Sciences [Milton Keynes], Faculty of Science, Technology, Engineering and Mathematics [Milton Keynes], The Open University [Milton Keynes] (OU)-The Open University [Milton Keynes] (OU), Commissariat à l'énergie atomique et aux énergies alternatives - Laboratoire d'Electronique et de Technologie de l'Information (CEA-LETI), Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Centre de Modélisation Mathématique / Centro de Modelamiento Matemático (CMM), Centre National de la Recherche Scientifique (CNRS), Centre d'étude spatiale des rayonnements (CESR), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire Midi-Pyrénées (OMP), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Météo-France -Institut de Recherche pour le Développement (IRD)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Météo-France -Centre National de la Recherche Scientifique (CNRS), Observatoire de Haute-Provence (OHP), Institut Pythéas (OSU PYTHEAS), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA)-Centre National de la Recherche Scientifique (CNRS), Australian Institute of Sport, International Parkinson's Centre of Excellence [Londres], King's College Hospital (KCH)-King‘s College London, Queen Elizabeth Hospital, Queens Elizabeth Hospital [Birmingham], Hospital Israelita Albert Einstein [São Paulo, Brazil], Department of Computing, Electronics and Mechatronics, Universidad de las Américas [Puebla] (UDLAP), Agenzia Spaziale Italiana (ASI), Géoazur (GEOAZUR 7329), Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de la Côte d'Azur, COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud]), Institut de recherches sur la catalyse et l'environnement de Lyon (IRCELYON), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome] (UNIROMA), Astrometry, Istituto Nazionale di Astrofisica (INAF)-Istituto Nazionale di Astrofisica (INAF), Universidade de Lisboa = University of Lisbon (ULISBOA), Department of Mechanical, Informatics and Aerospace Engineering [León], Universidad de León [León], Department of Physics [Athens], National and Kapodistrian University of Athens (NKUA), Departament Llenguatges i Sistemes Informatics, Universitat Politècnica de Catalunya [Barcelona] (UPC), Department of Astrophysics [Nijmegen], Institute for Mathematics, Astrophysics and Particle Physics (IMAPP), Radboud University [Nijmegen]-Radboud University [Nijmegen], SRON Netherlands Institute for Space Research (SRON), Institut d'Astronomie et d'Astrophysique [Bruxelles] (IAA), Université libre de Bruxelles (ULB), The Institute of Environmental Medicine [Stockholm] (IMM), Karolinska Institutet [Stockholm], INAF - Osservatorio Astrofisico di Catania (OACT), Institut de Physique de Rennes (IPR), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS), Shanghai Astronomical Observatory [Shanghai] (SHAO), Chinese Academy of Sciences [Beijing] (CAS), Astrophysics Research Institute [Liverpool] (ARI), Liverpool John Moores University (LJMU), INAF - Osservatorio Astronomico di Capodimonte (OAC), Matériaux, ingénierie et science [Villeurbanne] (MATEIS), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS), Center for Functional Analysis, Faculdade de Ciencias da Universidade de Lisboa, Istituto Nazionale di Astrofisica (Istituto Nazionale di Astrofisica), Istituto Nazionale di Fisica Nucleare (INFN), INAF - Osservatorio Astronomico di Trieste (OAT), Laboratoire SUBATECH Nantes (SUBATECH), Mines Nantes (Mines Nantes)-Université de Nantes (UN)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de l'Accélérateur Linéaire (LAL), Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Institut d'Astrophysique et de Géophysique [Liège], Université de Liège, Institute for Astronomy [Edinburgh] (IfA), Botanique et Modélisation de l'Architecture des Plantes et des Végétations (UMR AMAP), Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-Institut National de la Recherche Agronomique (INRA)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud]), GIRM, Instituto Politécnico de Leiria, LeanXcale [Madrid], Service de la Radio-Oncologie [Saint-Herblain], Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER-UNICANCER, Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Service de Neurologie [Hôpitaux Civils de Colmar], Hôpitaux Civils Colmar, Institute of Hepatology, Birkbeck College [University of London]-Foundation for Liver Research, Département Réseaux, Information, Multimédia (RIM-ENSMSE), École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Centre G2I, European Space Operations Center (ESOC), Équipes de Recherches Interlangues : Mémoires, Identités, Territoires (ERIMIT), Université de Rennes 2 (UR2), Université Paris 1 Panthéon-Sorbonne - UFR d'Économie (UP1 UFR02), Université Paris 1 Panthéon-Sorbonne (UP1), Department of Physics [Durham], University of New Hampshire (UNH), Spanish Virtual Observatory - Observatorio Virtual Español (SVO), Spanish Virtual Observatory - Observatorio Virtual Español, Departamento de Astrofisica [Madrid], Instituto Nacional de Técnica Aeroespacial (INTA)-Consejo Superior de Investigaciones Científicas [Madrid] (CSIC)-Instituto Nacional de Técnica Aeroespacial (INTA)-Consejo Superior de Investigaciones Científicas [Madrid] (CSIC), Department of Computer Science [Verona] (UNIVR | DI), Università degli studi di Verona = University of Verona (UNIVR), Geophysical Laboratory [Carnegie Institution], Carnegie Institution for Science, Konkoly Observatory, Research Centre for Astronomy and Earth Sciences [Budapest], Hungarian Academy of Sciences (MTA)-Hungarian Academy of Sciences (MTA), Instituto de Astronomia, Geofísica e Ciências Atmosféricas [São Paulo] (IAG), Universidade de São Paulo = University of São Paulo (USP), University of Paderborn, Karl-Franzens-Universität Graz, HE Space Operations BV for ESA/ESTEC, Institute of Hydrology, University of Freiburg [Freiburg], Laboratoire Electronique, Informatique et Image [UMR6306] (Le2i), Université de Bourgogne (UB)-École Nationale Supérieure d'Arts et Métiers (ENSAM), Arts et Métiers Sciences et Technologies, HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Arts et Métiers Sciences et Technologies, HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS), Department of Computer Science [Beer-Sheva], Ben-Gurion University of the Negev (BGU), CENTRA-SIM, IDL-Faculdade de Ciencias da Universidade de Lisboa, Westfälische Wilhelms-Universität Münster = University of Münster (WWU), Laboratoire de Physique des Lasers, Atomes et Molécules - UMR 8523 (PhLAM), Université de Lille-Centre National de la Recherche Scientifique (CNRS), Laboratori de Bromatologia i Toxicologia, Facultat de Farmàcia, Universitat de València (UV), Max-Planck-Institut für Sonnensystemforschung = Max Planck Institute for Solar System Research (MPS), Max-Planck-Gesellschaft, Manomet Center for Conservation Sciences, Unite mixte de recherche en droit comparé (UMRDC), Université Paris 1 Panthéon-Sorbonne (UP1)-Centre National de la Recherche Scientifique (CNRS), Canadian Food Inspection Agency (CFIA), Institut Jean-Nicod (IJN), Département d'Etudes Cognitives - ENS Paris (DEC), École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École des hautes études en sciences sociales (EHESS)-Collège de France (CdF (institution))-Centre National de la Recherche Scientifique (CNRS)-Département de Philosophie - ENS Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL), Universidade Estadual Paulista Júlio de Mesquita Filho = São Paulo State University (UNESP), Centre d'Immunologie de Marseille - Luminy (CIML), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Droit Privé et de Sciences Criminelles (LDPSC), Aix Marseille Université (AMU), Department of Physics and Astronomy [Clemson], Clemson University, Departamento de Producción Animal y Ciencia de los Alimentos, University of Zaragoza - Universidad de Zaragoza [Zaragoza], Département d'Astrophysique, de physique des Particules, de physique Nucléaire et de l'Instrumentation Associée (DAPNIA), Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Lineberger Comprehensive Cancer Center (UNC Lineberger), University of North Carolina [Chapel Hill] (UNC), University of North Carolina System (UNC)-University of North Carolina System (UNC), Uppsala University, Center for Ultrafast Optical Science, University of Michigan [Ann Arbor], University of Michigan System-University of Michigan System, Department of Psychiatry, Seaver Autism Center for Research and Treatment, European Southern Observatory (ESO), Centre interuniversitaire de recherche et d'ingenierie des matériaux (CIRIMAT), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT), Leibniz Institute for Astrophysics Potsdam (AIP), Innovalia Association, University of Las Palmas de Gran Canaria (ULPGC), Department of Physics [Helsinki], Falculty of Science [Helsinki], Helsingin yliopisto = Helsingfors universitet = University of Helsinki-Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Nordic Optical Telescope (NOT), Instituto de Astrofisica de Canarias (IAC), Royal Institute of Technology [Stockholm] (KTH ), Leiden Observatory [Leiden], Universiteit Leiden, Institut d'Astrophysique de Paris (IAP), Institut national des sciences de l'Univers (INSU - CNRS)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Leibniz-Institut für Astrophysik Potsdam (AIP), Universidade de Coimbra [Coimbra], Southwest Research Institute [Boulder] (SwRI), Max-Planck-Institut für Astronomie (MPIA), University of the Western Cape (UWC), Istituto di Radioastronomia [Bologna] (IRA), Observatoire astronomique de Strasbourg (OAS), Institut national des sciences de l'Univers (INSU - CNRS)-Université Louis Pasteur - Strasbourg I-Centre National de la Recherche Scientifique (CNRS), Centre d'études spatiales de la biosphère (CESBIO), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Météo-France -Institut national des sciences de l'Univers (INSU - CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Météo-France -Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Lohrmann Observatory, Technische Universität Dresden = Dresden University of Technology (TU Dresden), European Space Agency (ESA), PSL Research University (PSL)-PSL Research University (PSL)-Centre National de la Recherche Scientifique (CNRS), Universität Heidelberg [Heidelberg], University of Bergen (UIB)-University of Bergen (UIB), University of Bergen (UIB), University of Geneva [Switzerland], Agence Spatiale Européenne (ESA), Human Cancer Genetics Program, Comprehensive Cancer Center-College of Medicine and Public Health [Colombus], M2A 2016, Université de Bordeaux (UB)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université de Bordeaux (UB)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS), Ecologie, Evolution, Symbiose (EES), Ecologie et biologie des interactions (EBI), Université de Poitiers-Centre National de la Recherche Scientifique (CNRS)-Université de Poitiers-Centre National de la Recherche Scientifique (CNRS), University of Illinois at Urbana Champaign (UIUC), University of Illinois at Urbana-Champaign [Urbana], University of Illinois System-University of Illinois System, University of California, Department of Biomedical Sciences, Università degli Studi di Modena e Reggio Emilia (UNIMORE), Nelson Mandela Metropolitan University [Port Elizabeth, South Africa], Laboratorio de Inmunologıa y Virologıa, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolas de los Garza, Solvay (France), Université Nice Sophia Antipolis (... - 2019) (UNS), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Observatoire de la Côte d'Azur, Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Caractéristiques féminines des dysfonctions des interfaces cardio-vasculaires (EA 2992), Université Montpellier 1 (UM1)-Université de Montpellier (UM), PSL Research University (PSL)-PSL Research University (PSL)-Université de Lille-Centre National de la Recherche Scientifique (CNRS), Royal Observatory of Belgium [Brussels], Università di Bologna [Bologna] (UNIBO), Université Paris-Sud - Paris 11 (UP11)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS), Universidade Federal de Rondônia, Institute of Astronomy, Université de Montpellier (UM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Department of Pathology and Cell Biology, Columbia University [New York], AUTRES, EURIX (.), Laboratoire Récepteurs et Canaux Ioniques Membranaires (RCIM), IDAEA-CSIC, THALES, Laboratoire d'Ecologie Alpine (LECA), Centre National de la Recherche Scientifique (CNRS)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Université Joseph Fourier - Grenoble 1 (UJF)-Université Grenoble Alpes (UGA), Centre National d'Études Spatiales [Toulouse] (CNES)-Université Grenoble Alpes (UGA)-Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire des Sciences de l'Univers de Grenoble (OSUG), Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA)-Université Joseph Fourier - Grenoble 1 (UJF)-Centre National de la Recherche Scientifique (CNRS), Université Côte d'Azur (UCA), Université Sciences et Technologies - Bordeaux 1-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS), Université de Genève (UNIGE), Université Grenoble Alpes - UFR Langage, lettres et arts du spectacle, information et communication - Dpt Lettres et arts du spectacle (UGA UFR LLASIC LAS), Université Grenoble Alpes (UGA), Institut de Chimie Moléculaire de Reims - UMR 7312 (ICMR), SFR Condorcet, Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Centre National de la Recherche Scientifique (CNRS)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Centre National de la Recherche Scientifique (CNRS)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Centre National de la Recherche Scientifique (CNRS), Instituto Nacional de Técnica Aeroespacial (INTA)-Consejo Superior de Investigaciones Científicas [Spain] (CSIC), FORMATION STELLAIRE 2016, The Open University [Milton Keynes] (OU), CICEnergigune, Laboratoire d'Electronique et des Technologies de l'Information (CEA-LETI), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes (UGA), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire Midi-Pyrénées (OMP), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), Hospital Israelita Albert Einstein, Pneumologia Ospedale San Paolo, Università degli studi di Milano [Milano], Activité Physique, Muscle, Santé (EA4488), Université de Lille, Droit et Santé, Scuola Internazionale Superiore di Studi Avanzati / International School for Advanced Studies (SISSA / ISAS), Institut national des sciences de l'Univers (INSU - CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud])-Centre National de la Recherche Scientifique (CNRS)-Observatoire de la Côte d'Azur, Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Università degli Studi di Roma 'La Sapienza' [Rome], Biologie Intégrative des Populations, École pratique des hautes études (EPHE)-Centre National de la Recherche Scientifique (CNRS), Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Matériaux et nanosciences d'Alsace, Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Réseau nanophotonique et optique, Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA), Federal University of Para - Universidade Federal do Para [Belem - Brésil], Sciences Pour l'Oenologie (SPO), Université Montpellier 1 (UM1)-Institut de Recherche pour le Développement (IRD [Nouvelle-Calédonie])-Institut National de la Recherche Agronomique (INRA)-Université de Montpellier (UM)-Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro), National and Kapodistrian University of Athens = University of Athens (NKUA | UoA), Heckscher-Klinikum, Radboud university [Nijmegen]-Radboud university [Nijmegen], Institut d'Astronomie et d'Astrophysique, Université Libre de Bruxelles [Bruxelles] (ULB), Biologie et pharmacologie des plaquettes sanguines: hémostase, thrombose, transfusion (http://www.u949.inserm.fr/), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-EFS, Virulence bactérienne et maladies infectieuses (VBMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS), Institut de chimie et procédés pour l'énergie, l'environnement et la santé (ICPEES), Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de Chimie de Clermont-Ferrand (ICCF), Centre National de la Recherche Scientifique (CNRS)-Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Sigma CLERMONT (Sigma CLERMONT), Atmel Corporation (ATMEL), ATMEL, Probabilités, statistique, physique mathématique (PSPM), Institut Camille Jordan [Villeurbanne] (ICJ), École Centrale de Lyon (ECL), Université de Lyon-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet [Saint-Étienne] (UJM)-Centre National de la Recherche Scientifique (CNRS)-École Centrale de Lyon (ECL), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet [Saint-Étienne] (UJM)-Centre National de la Recherche Scientifique (CNRS), Institut Non Linéaire de Nice Sophia-Antipolis (INLN), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Université Paris-Sorbonne - Paris 4 - École supérieure du professorat et de l'éducation - Académie de Paris (ESPE Paris), Université Paris-Sorbonne (UP4), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA), UCT/MRC Receptor Biology Unit, University of Cape Town, Mammal Research Institute, University of Pretoria [South Africa], Centre for Integrative Physiology, Physics and Materials Science Research Unit, University of Luxembourg, University of Luxembourg [Luxembourg], Institut de Recherche sur la Fusion par confinement Magnétique (IRFM), National Institute for Nuclear Physics (INFN), Departamento de Microbiología y Parasitología [Lugo, Spain], Laboratorio de Referencia de E. coli [Lugo, Spain] (LREC), Universidade de Santiago de Compostela [Spain] (USC )-Universidade de Santiago de Compostela [Spain] (USC ), CERFACS [Toulouse], Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS), Molecular Neuroimaging, RedZinc Services Ltd.[Dublin], Laboratoire de Physico -& Toxico Chimie des systèmes naturels (LPTC), Université Sciences et Technologies - Bordeaux 1-Centre National de la Recherche Scientifique (CNRS), Institut de Cancérologie de l'Ouest- ICO Gauducheau, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP]-Centre National de la Recherche Scientifique (CNRS), Department of Biochemical and Chemical Engineering, Technische Universität Dortmund [Dortmund] (TU), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Université Panthéon-Sorbonne - UFR d'Économie (UP1 UFR02), Université Panthéon-Sorbonne (UP1), Capital Normal University [Beijing], Department of Paleobiology [Washington], Smithsonian Institution, Instituto Nacional de Técnica Aeroespacial (INTA)-Consejo Superior de Investigaciones Científicas [Spain] (CSIC)-Instituto Nacional de Técnica Aeroespacial (INTA)-Consejo Superior de Investigaciones Científicas [Spain] (CSIC), Università degli Studi di Verona, Carnegie Institution for Science [Washington], Instituto de Astronomia, Geofisica e Ciencias Atmosfericas [Sao Paulo] (IAG), Universidade de São Paulo (USP), HESAM Université (HESAM)-HESAM Université (HESAM)-Arts et Métiers Sciences et Technologies, HESAM Université (HESAM)-HESAM Université (HESAM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS), Westfälische Wilhelms-Universität Münster (WWU), Max-Planck-Institut für Sonnensystemforschung (MPS), Université Panthéon-Sorbonne (UP1)-Centre National de la Recherche Scientifique (CNRS), Centre universitaire de Cytométrie, Imagerie et Mathématiques (CIM), Université de Limoges (UNILIM)-CHU Limoges, Département de Philosophie - ENS Paris, École normale supérieure - Paris (ENS Paris)-École normale supérieure - Paris (ENS Paris)-Centre National de la Recherche Scientifique (CNRS)-École des hautes études en sciences sociales (EHESS)-Département d'Etudes Cognitives - ENS Paris (DEC), École normale supérieure - Paris (ENS Paris), Universidade Estadual Paulista Júlio de Mesquita Filho [São José do Rio Preto] (UNESP), Laboratoire d'Etudes Sociolinguistiques sur les Contacts de Langues et la Politique Linguistique (LESCLAP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), Lineberger Comprehensive Cancer Center, Centre de Recherches Pétrographiques et Géochimiques (CRPG), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées, University of Helsinki-University of Helsinki, Institute of Space and Astronautical Science (ISAS), Instituto de Astrofísica de Andalucía (IAA), Consejo Superior de Investigaciones Científicas [Spain] (CSIC), Instituto Nacional de Engenharia, Tecnologia e Inovacco (INETI), Réhabilitation Chirurgicale mini-Invasive et Robotisée de l'Audition, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Otologie, Implants auditifs et Chirurgie de la base du crâne [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Sonoita Research Observatory, Laboratoire Microorganismes : Génome et Environnement (LMGE), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Université d'Auvergne - Clermont-Ferrand I (UdA)-Centre National de la Recherche Scientifique (CNRS), Institute of Physical Geodesy, sans affiliation, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Observatoire Midi-Pyrénées (OMP), Université Fédérale Toulouse Midi-Pyrénées-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS), Technische Universität Dresden (TUD), ITA, Université Côte d'Azur (UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Universität Heidelberg [Heidelberg]-Universität Heidelberg [Heidelberg], Centre National de la Recherche Scientifique (CNRS)-Université de Lille-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Montpellier 2 - Sciences et Techniques (UM2), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS), Consejo Superior de Investigaciones Científicas [Madrid] (CSIC)-Instituto Nacional de Técnica Aeroespacial (INTA), Observatoire Midi-Pyrénées (OMP), Météo France-Centre National d'Études Spatiales [Toulouse] (CNES)-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Météo France-Centre National d'Études Spatiales [Toulouse] (CNES)-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Toulouse III - Paul Sabatier (UT3), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)-Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)-Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA)-Institut de Recherche pour le Développement (IRD), Université Côte d'Azur (UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud])-Centre National de la Recherche Scientifique (CNRS)-Observatoire de la Côte d'Azur, Université Côte d'Azur (UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], Universidade de Lisboa (ULISBOA), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université de Nantes (UN)-Mines Nantes (Mines Nantes), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Institut National de la Recherche Agronomique (INRA)-Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-Institut de Recherche pour le Développement (IRD [France-Sud]), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Consejo Superior de Investigaciones Científicas [Madrid] (CSIC)-Instituto Nacional de Técnica Aeroespacial (INTA)-Consejo Superior de Investigaciones Científicas [Madrid] (CSIC)-Instituto Nacional de Técnica Aeroespacial (INTA), University of Verona (UNIVR), Université de Bourgogne (UB)-Centre National de la Recherche Scientifique (CNRS)-École Nationale Supérieure d'Arts et Métiers (ENSAM), HESAM Université (HESAM)-HESAM Université (HESAM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS Paris), Centre d'Etudes des Relations et Contacts Linguistiques et Littéraires - UR UPJV 4283 (CERCLL), Institut national des sciences de l'Univers (INSU - CNRS)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC), Universiteit Leiden [Leiden], University of the Western Cape, Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Toulouse III - Paul Sabatier (UT3), Météo France-Centre National d'Études Spatiales [Toulouse] (CNES)-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Météo France-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS), European Space Research and Technology Centre ( ESTEC ), European Space Agency ( ESA ), University of Bergen ( UIB ) -University of Bergen ( UIB ), University of Bergen ( UIB ), Centre for Research in Earth and Space Science [Toronto] ( CRESS ), Agence Spatiale Européenne ( ESA ), Laboratoire d'Astrophysique de Bordeaux [Pessac] ( LAB ), Université de Bordeaux ( UB ) -Institut national des sciences de l'Univers ( INSU - CNRS ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Bordeaux ( UB ) -Institut national des sciences de l'Univers ( INSU - CNRS ) -Centre National de la Recherche Scientifique ( CNRS ), Equipe EES, Ecologie et biologie des interactions ( EBI ), Université de Poitiers-Centre National de la Recherche Scientifique ( CNRS ) -Université de Poitiers-Centre National de la Recherche Scientifique ( CNRS ), Katholieke Universiteit Leuven ( KU Leuven ), University of Illinois at Urbana Champaign ( UIUC ), Departments of Neurosciences, Radiology, Psychiatry, and Cognitive Science, University of California, San Diego, La Jolla, CA 92093-0841, USA, Centre National d'Etudes Spatiales ( CNES ), University of Modena & Reggio-Emilia, Galaxies, Etoiles, Physique, Instrumentation ( GEPI ), Institut national des sciences de l'Univers ( INSU - CNRS ) -Observatoire de Paris-Université Paris Diderot - Paris 7 ( UPD7 ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire Lagrange - Observatoire de la Côte d'Azur, Université Nice Sophia Antipolis ( UNS ), Université Côte d'Azur ( UCA ) -Université Côte d'Azur ( UCA ) -Centre National de la Recherche Scientifique ( CNRS ), European Space Astronomy Centre ( ESAC ), Caractéristiques féminines des dysfonctions des interfaces cardio-vasculaires ( EA 2992 ), Université Montpellier 1 ( UM1 ) -Université de Montpellier ( UM ), Systèmes de Référence Temps Espace ( SYRTE ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut national des sciences de l'Univers ( INSU - CNRS ) -Observatoire de Paris-Centre National de la Recherche Scientifique ( CNRS ), Mullard Space Science Laboratory ( MSSL ), University College of London [London] ( UCL ), Institut de Mécanique Céleste et de Calcul des Ephémérides ( IMCCE ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut national des sciences de l'Univers ( INSU - CNRS ) -Observatoire de Paris-Université de Lille-Centre National de la Recherche Scientifique ( CNRS ), Università di Bologna [Bologna] ( UNIBO ), Institut d'astrophysique spatiale ( IAS ), Université Paris-Sud - Paris 11 ( UP11 ) -Institut national des sciences de l'Univers ( INSU - CNRS ) -Centre National de la Recherche Scientifique ( CNRS ), Université de Picardie Jules Verne ( UPJV ), University of Cambridge [UK] ( CAM ), Laboratoire Univers et Particules de Montpellier ( LUPM ), Centre National de la Recherche Scientifique ( CNRS ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Université Montpellier 2 - Sciences et Techniques ( UM2 ) -Université de Montpellier ( UM ), SIM/IDL Faculdade de Ciências da Universidade de Lisboa ( FCUL ), Lisboa university, Univers, Transport, Interfaces, Nanostructures, Atmosphère et environnement, Molécules (UMR 6213) ( UTINAM ), Institut national des sciences de l'Univers ( INSU - CNRS ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), Florida State University, INTA ( INTA ), United States Geological Survey [Reston] ( USGS ), Laboratoire Récepteurs et Canaux Ioniques Membranaires ( RCIM ), Université d'Angers ( UA ) -Institut National de la Recherche Agronomique ( INRA ), Mount Sinai School of Medicine, Universitat de Barcelona ( UB ), Laboratoire d'Ecologie Alpine ( LECA ), Centre National de la Recherche Scientifique ( CNRS ) -Université Savoie Mont Blanc ( USMB [Université de Savoie] [Université de Chambéry] ) -Université Joseph Fourier - Grenoble 1 ( UJF ) -Université Grenoble Alpes ( UGA ), Institut de Planétologie et d'Astrophysique de Grenoble ( IPAG ), Observatoire des Sciences de l'Univers de Grenoble ( OSUG ), Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut national des sciences de l'Univers ( INSU - CNRS ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ) -Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut national des sciences de l'Univers ( INSU - CNRS ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ) -Centre National de la Recherche Scientifique ( CNRS ), Université Côte d'Azur ( UCA ), Université de Bordeaux ( UB ) -Institut national des sciences de l'Univers ( INSU - CNRS ) -Centre National de la Recherche Scientifique ( CNRS ), Observatoire aquitain des sciences de l'univers ( OASU ), Université Sciences et Technologies - Bordeaux 1-Institut national des sciences de l'Univers ( INSU - CNRS ) -Centre National de la Recherche Scientifique ( CNRS ), Observatoire Astronomique de l'Université de Genève ( ObsGE ), Université de Genève ( UNIGE ), Université Grenoble Alpes - UFR Langage, lettres et arts du spectacle, information et communication - Dpt Lettres et arts du spectacle ( UGA UFR LLASIC LAS ), Université Grenoble Alpes ( UGA ), Institut de Chimie Moléculaire de Reims - UMR 7312 ( ICMR ), Université de Reims Champagne-Ardenne ( URCA ) -Université de Picardie Jules Verne ( UPJV ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Reims Champagne-Ardenne ( URCA ) -Université de Picardie Jules Verne ( UPJV ) -Centre National de la Recherche Scientifique ( CNRS ) -SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne ( URCA ) -Université de Picardie Jules Verne ( UPJV ) -Université de Reims Champagne-Ardenne ( URCA ) -Université de Picardie Jules Verne ( UPJV ) -Université de Reims Champagne-Ardenne ( URCA ) -Centre National de la Recherche Scientifique ( CNRS ), Centro de Astrobiologia [Madrid] ( CAB ), Instituto Nacional de Técnica Aeroespacial ( INTA ) -Consejo Superior de Investigaciones Científicas [Spain] ( CSIC ), The Open University [Milton Keynes] ( OU ), Laboratoire d'Electronique et des Technologies de l'Information ( CEA-LETI ), Université Grenoble Alpes [Saint Martin d'Hères]-Direction de Recherche Technologique (CEA) ( DRT (CEA) ), Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ), Centre de Modélisation Mathématique / Centro de Modelamiento Matemático ( CMM ), Centre National de la Recherche Scientifique ( CNRS ), Centre de Recherches Anglophones ( CREA (EA 370) ), Université Paris Nanterre ( UPN ), Centre d'étude spatiale des rayonnements ( CESR ), Université Toulouse III - Paul Sabatier ( UPS ), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut national des sciences de l'Univers ( INSU - CNRS ) -Observatoire Midi-Pyrénées ( OMP ) -Centre National de la Recherche Scientifique ( CNRS ), Observatoire de Haute-Provence ( OHP ), Institut Pythéas ( OSU PYTHEAS ), Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture ( IRSTEA ) -Institut de Recherche pour le Développement ( IRD ) -Aix Marseille Université ( AMU ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture ( IRSTEA ) -Institut de Recherche pour le Développement ( IRD ) -Aix Marseille Université ( AMU ) -Centre National de la Recherche Scientifique ( CNRS ), King's College Hospital-King‘s College London, Universidad de las Américas [Puebla] ( UDLAP ), Activité Physique, Muscle, Santé ( EA4488 ), Scuola Internazionale Superiore di Studi Avanzati / International School for Advanced Studies ( SISSA / ISAS ), INAF - Osservatorio Astronomico di Bologna ( OABO ), Istituto Nazionale di Astrofisica ( INAF ), Géoazur ( GEOAZUR ), Université Côte d'Azur ( UCA ) -Université Côte d'Azur ( UCA ) -Institut national des sciences de l'Univers ( INSU - CNRS ) -Observatoire de la Côte d'Azur, Université Côte d'Azur ( UCA ) -Centre National de la Recherche Scientifique ( CNRS ), Institut de recherches sur la catalyse et l'environnement de Lyon ( IRCELYON ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique ( CNRS ), École pratique des hautes études ( EPHE ) -Centre National de la Recherche Scientifique ( CNRS ), INAF - Osservatorio Astrofisico di Torino ( OATo ), Istituto Nazionale di Astrofisica ( INAF ) -Istituto Nazionale di Astrofisica ( INAF ), Institut de Physique et Chimie des Matériaux de Strasbourg ( IPCMS ), Université de Strasbourg ( UNISTRA ) -Centre National de la Recherche Scientifique ( CNRS ) -Matériaux et nanosciences d'Alsace, Université de Strasbourg ( UNISTRA ) -Université de Haute-Alsace (UHA) Mulhouse - Colmar ( Université de Haute-Alsace (UHA) ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Strasbourg ( UNISTRA ) -Université de Haute-Alsace (UHA) Mulhouse - Colmar ( Université de Haute-Alsace (UHA) ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Réseau nanophotonique et optique, Université de Strasbourg ( UNISTRA ) -Université de Haute-Alsace (UHA) Mulhouse - Colmar ( Université de Haute-Alsace (UHA) ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Strasbourg ( UNISTRA ), University of León, Observatoire astronomique de Strasbourg ( ObAS ), Université de Strasbourg ( UNISTRA ) -Institut national des sciences de l'Univers ( INSU - CNRS ) -Centre National de la Recherche Scientifique ( CNRS ), Sciences Pour l'Oenologie ( SPO ), Institut National de la Recherche Agronomique ( INRA ) -Institut de Recherche pour le Développement ( IRD [Nouvelle-Calédonie] ) -Université de Montpellier ( UM ) -Université Montpellier 1 ( UM1 ) -Institut national d’études supérieures agronomiques de Montpellier ( Montpellier SupAgro ), Department of Physics (Athens), Universitat Politècnica de Catalunya [Barcelona] ( UPC ), Laboratoire d'Ingénierie des Systèmes Biologiques et des Procédés ( LISBP ), Institut National de la Recherche Agronomique ( INRA ) -Institut National des Sciences Appliquées - Toulouse ( INSA Toulouse ), Institut National des Sciences Appliquées ( INSA ) -Institut National des Sciences Appliquées ( INSA ) -Centre National de la Recherche Scientifique ( CNRS ), Institute for Mathematics, Astrophysics and Particle Physics ( IMAPP ), SRON Netherlands Institute for Space Research ( SRON ), Université Libre de Bruxelles [Bruxelles] ( ULB ), The Institute of Environmental Medicine [Stockholm] ( IMM ), Biologie et pharmacologie des plaquettes sanguines: hémostase, thrombose, transfusion ( http://www.u949.inserm.fr/ ), Université de Strasbourg ( UNISTRA ) -EFS-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Virulence bactérienne et maladies infectieuses, Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Montpellier ( UM ), Institut de Physique de Rennes ( IPR ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Centre National de la Recherche Scientifique ( CNRS ), Institut de chimie et procédés pour l'énergie, l'environnement et la santé ( ICPEES ), Université de Strasbourg ( UNISTRA ) -Université de Haute-Alsace (UHA) Mulhouse - Colmar ( Université de Haute-Alsace (UHA) ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Strasbourg ( UNISTRA ) -Université de Haute-Alsace (UHA) Mulhouse - Colmar ( Université de Haute-Alsace (UHA) ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Institut de Chimie de Clermont-Ferrand ( ICCF ), Université Blaise Pascal - Clermont-Ferrand 2 ( UBP ) -Sigma CLERMONT ( Sigma CLERMONT ) -Centre National de la Recherche Scientifique ( CNRS ), Chinese Academy of Sciences [Beijing] ( CAS ), Atmel Corporation ( ATMEL ), Institut Camille Jordan [Villeurbanne] ( ICJ ), Centre National de la Recherche Scientifique ( CNRS ) -Université Jean Monnet [Saint-Étienne] ( UJM ) -École Centrale de Lyon ( ECL ), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon ( INSA Lyon ), Université de Lyon-Institut National des Sciences Appliquées ( INSA ) -Institut National des Sciences Appliquées ( INSA ) -Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon, Astrophysics Research Institute [Liverpool] ( ARI ), Liverpool John Moores University ( LJMU ), Institut Non Linéaire de Nice Sophia-Antipolis ( INLN ), École supérieure du professorat et de l'éducation - Académie de Paris ( ESPE Paris ), Université Paris-Sorbonne ( UP4 ), Matériaux, ingénierie et science [Villeurbanne] ( MATEIS ), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique ( CNRS ) -Institut National des Sciences Appliquées de Lyon ( INSA Lyon ), Université de Lyon-Institut National des Sciences Appliquées ( INSA ) -Institut National des Sciences Appliquées ( INSA ), Istituto Nazionale di Astrofisica ( Istituto Nazionale di Astrofisica ), National Institute for Nuclear Physics ( INFN ), INAF - Osservatorio Astronomico di Trieste ( OAT ), Laboratoire SUBATECH Nantes ( SUBATECH ), Mines Nantes ( Mines Nantes ) -Université de Nantes ( UN ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire de l'Accélérateur Linéaire ( LAL ), Université Paris-Sud - Paris 11 ( UP11 ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratorio de Referencia de E. coli [Lugo, Spain] ( LREC ), Universidade de Santiago de Compostela [A Coruña, Spain] ( USC ) -Universidade de Santiago de Compostela [A Coruña, Spain] ( USC ), Institut national des sciences de l'Univers ( INSU - CNRS ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire de Physico -& Toxico Chimie des systèmes naturels ( LPTC ), Université Sciences et Technologies - Bordeaux 1-Centre National de la Recherche Scientifique ( CNRS ), Botanique et Modélisation de l'Architecture des Plantes et des Végétations ( UMR AMAP ), Centre de Coopération Internationale en Recherche Agronomique pour le Développement ( CIRAD ) -Institut national de la recherche agronomique [Montpellier] ( INRA Montpellier ) -Université de Montpellier ( UM ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut de Recherche pour le Développement ( IRD [France-Sud] ), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute ( ICM ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -CHU Pitié-Salpêtrière [APHP]-Centre National de la Recherche Scientifique ( CNRS ), Département Réseaux, Information, Multimédia ( RIM-ENSMSE ), École des Mines de Saint-Étienne ( Mines Saint-Étienne MSE ), Institut Mines-Télécom [Paris]-Institut Mines-Télécom [Paris]-Centre G2I, European Space Operations Center ( ESOC ), Technische Universität Dortmund [Dortmund] ( TU ), Équipes de Recherches Interlangues : Mémoires, Identités, Territoires ( ERIMIT ), Université de Rennes 2 ( UR2 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ), Université Panthéon-Sorbonne - UFR d'Économie ( UP1 UFR02 ), Université Panthéon-Sorbonne ( UP1 ), University of New Hampshire ( UNH ), Spanish Virtual Observatory - Observatorio Virtual Español ( SVO ), Centro de Astrobiologia, Departamento de Astrofisica ( INTA-CSIC ), Centro de Astrobiología, Konkoly Observatory, Research Centre for Astronomy and Earth Sciences, Hungarian Academy of Sciences [Budapest], Instituto de Astronomia, Geofisica e Ciencias Atmosfericas [Sao Paulo] ( IAG ), Universidade de São Paulo ( USP ), Physikalisch Technische Bundesanstalt ( PTB ), Laboratoire Electronique, Informatique et Image [UMR6303] ( Le2i ), Centre National de la Recherche Scientifique ( CNRS ) -Université de Bourgogne ( UB ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-École Nationale Supérieure d'Arts et Métiers ( ENSAM ), Ben-Gurion University of the Negev ( BGU ), Ben Gurion University, Westfälische Wilhelms-Universität Münster ( WWU ), Laboratoire de Physique des Lasers, Atomes et Molécules - UMR 8523 ( PhLAM ), Université de Lille-Centre National de la Recherche Scientifique ( CNRS ), Joseph Louis LAGRANGE ( LAGRANGE ), Université Côte d'Azur ( UCA ) -Université Côte d'Azur ( UCA ) -Observatoire de la Côte d'Azur, Universitat de València ( UV ), Max-Planck-Institut für Sonnensystemforschung ( MPS ), Unite mixte de recherche en droit comparé ( UMRDC ), Université Panthéon-Sorbonne ( UP1 ) -Centre National de la Recherche Scientifique ( CNRS ), Centre universitaire de Cytométrie, Imagerie et Mathématiques ( CIM ), Université de Limoges ( UNILIM ) -CHU Limoges, Institut Cochin ( IC UM3 (UMR 8104 / U1016) ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Canadian Food Inspection Agency ( CFIA ), Institut Jean-Nicod ( IJN ), Département d'Etudes Cognitives - ENS Paris ( DEC ), École normale supérieure - Paris ( ENS Paris ) -École normale supérieure - Paris ( ENS Paris ) -École des hautes études en sciences sociales ( EHESS ) -Centre National de la Recherche Scientifique ( CNRS ) -Département de Philosophie - ENS Paris, École normale supérieure - Paris ( ENS Paris ), Universidade Estadual Paulista, Laboratoire d'Etudes Sociolinguistiques sur les Contacts de Langues et la Politique Linguistique ( LESCLAP ), Centre d'Immunologie de Marseille - Luminy ( CIML ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Aix Marseille Université ( AMU ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire de Droit Privé et de Sciences Criminelles ( LDPSC ), Aix Marseille Université ( AMU ), Clemson University [USA], University of Zaragoza, Département d'Astrophysique, de physique des Particules, de physique Nucléaire et de l'Instrumentation Associée ( DAPNIA ), Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ), The University of North Carolina at Chapel Hill, Icahn School of Medicine at Mount Sinai [New York], European Southern Observatory ( ESO ), Centre de Recherches Pétrographiques et Géochimiques ( CRPG ), Université de Lorraine ( UL ) -Centre National de la Recherche Scientifique ( CNRS ), Centre interuniversitaire de recherche et d'ingenierie des matériaux ( CIRIMAT ), Institut National Polytechnique [Toulouse] ( INP ) -Université Toulouse III - Paul Sabatier ( UPS ), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique ( CNRS ), Astrophysikalisches Institut Potsdam, University of Las Palmas de Gran Canaria ( ULPGC ), University of Helsinki [Helsinki], Nordic Optical Telescope ( NOT ), Instituto de Astrofisica de Canarias ( IAC ), Royal Institute of Technology [Stockholm] ( KTH ), Institute of Space and Astronautical Science ( ISAS ), Instituto de Astrofísica de Andalucía ( IAA ), Consejo Superior de Investigaciones Científicas [Spain] ( CSIC ), Instituto Nacional de Engenharia, Tecnologia e Inovacco ( INETI ), INETI, Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Laboratoire Microorganismes : Génome et Environnement ( LMGE ), Université Blaise Pascal - Clermont-Ferrand 2 ( UBP ) -Université d'Auvergne - Clermont-Ferrand I ( UdA ) -Centre National de la Recherche Scientifique ( CNRS ), Observatoire astronomique de Strasbourg ( OAS ), Institut national des sciences de l'Univers ( INSU - CNRS ) -Université Louis Pasteur - Strasbourg I-Centre National de la Recherche Scientifique ( CNRS ), Centre d'études spatiales de la biosphère ( CESBIO ), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut national des sciences de l'Univers ( INSU - CNRS ) -Observatoire Midi-Pyrénées ( OMP ) -Centre National d'Etudes Spatiales ( CNES ) -Centre National de la Recherche Scientifique ( CNRS ), Technische Universität Dresden ( TUD ), European Space Astronomy Center ( ESAC ), Géosciences Rennes ( GR ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Institut national des sciences de l'Univers ( INSU - CNRS ) -Observatoire des Sciences de l'Univers de Rennes ( OSUR ) -Centre National de la Recherche Scientifique ( CNRS ), Université Montpellier 2 - Sciences et Techniques ( UM2 ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Université de Montpellier ( UM ) -Centre National de la Recherche Scientifique ( CNRS ), Université de Franche-Comté ( UFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut national des sciences de l'Univers ( INSU - CNRS ), Université Joseph Fourier - Grenoble 1 ( UJF ) -Université Savoie Mont Blanc ( USMB [Université de Savoie] [Université de Chambéry] ) -Centre National de la Recherche Scientifique ( CNRS ), Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Université Grenoble Alpes [Saint Martin d'Hères], Institut Armand Frappier ( INRS-IAF ), Institut National de la Recherche Scientifique [Québec] ( INRS ) -Réseau International des Instituts Pasteur ( RIIP ) -Institut Armand Frappier, Université Montpellier 1 ( UM1 ) -Institut de Recherche pour le Développement ( IRD [Nouvelle-Calédonie] ) -Institut National de la Recherche Agronomique ( INRA ) -Université de Montpellier ( UM ) -Institut national d’études supérieures agronomiques de Montpellier ( Montpellier SupAgro ), Université de Strasbourg ( UNISTRA ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -EFS, Université de Montpellier ( UM ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), École Centrale de Lyon ( ECL ), Université de Lyon-Université de Lyon-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Institut National des Sciences Appliquées de Lyon ( INSA Lyon ), Université de Lyon-Institut National des Sciences Appliquées ( INSA ) -Institut National des Sciences Appliquées ( INSA ) -Université Jean Monnet [Saint-Étienne] ( UJM ) -Centre National de la Recherche Scientifique ( CNRS ), Institut de Recherche sur la Fusion par confinement Magnétique ( IRFM ), UNH Department of Physics [Durham], Université de Bourgogne ( UB ) -École Nationale Supérieure d'Arts et Métiers ( ENSAM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique ( CNRS ), Institut Cochin ( UM3 (UMR 8104 / U1016) ), Lille - Economie et Management ( LEM ), Centre National de la Recherche Scientifique ( CNRS ) -Université catholique de Lille ( UCL ) -Université de Lille, Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ), Université Blaise Pascal - Clermont-Ferrand 2 ( UBP ) -Centre National de la Recherche Scientifique ( CNRS ) -Université d'Auvergne - Clermont-Ferrand I ( UdA ), Centre National d'Etudes Spatiales (CNES), Centre National de la Recherche Scientifique (CNRS)-Université Paris Diderot - Paris 7 (UPD7)-Observatoire de Paris, PSL Research University (PSL)-PSL Research University (PSL)-Institut national des sciences de l'Univers (INSU - CNRS), Université Nice Sophia Antipolis (UNS), Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-Observatoire des Sciences de l'Univers de Grenoble (OSUG), Université Joseph Fourier - Grenoble 1 (UJF)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Université Toulouse III - Paul Sabatier (UPS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire Midi-Pyrénées (OMP)-Centre National de la Recherche Scientifique (CNRS), Géoazur (GEOAZUR), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de la Côte d'Azur, Institut National de la Recherche Agronomique (INRA)-Institut de Recherche pour le Développement (IRD [Nouvelle-Calédonie])-Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro)-Université de Montpellier (UM)-Université Montpellier 1 (UM1), Laboratoire d'Ingénierie des Systèmes Biologiques et des Procédés (LISBP), Institut National de la Recherche Agronomique (INRA)-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS), Université de Strasbourg (UNISTRA)-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Sigma CLERMONT (Sigma CLERMONT)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Université Jean Monnet [Saint-Étienne] (UJM)-École Centrale de Lyon (ECL), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Université Jean Monnet [Saint-Étienne] (UJM)-École Centrale de Lyon (ECL), Universidade de Santiago de Compostela [A Coruña, Spain] (USC )-Universidade de Santiago de Compostela [A Coruña, Spain] (USC ), Centre de Coopération Internationale en Recherche Agronomique pour le Développement (CIRAD)-Institut national de la recherche agronomique [Montpellier] (INRA Montpellier)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud]), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [APHP], Centro de Astrobiologia, Departamento de Astrofisica (INTA-CSIC), Laboratoire Electronique, Informatique et Image [UMR6303] (Le2i), Université de Bourgogne (UB)-École Nationale Supérieure d'Arts et Métiers (ENSAM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Institut National Polytechnique [Toulouse] (INP)-Université Toulouse III - Paul Sabatier (UPS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire Midi-Pyrénées (OMP)-Centre National d'Etudes Spatiales (CNES)-Centre National de la Recherche Scientifique (CNRS), Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Observatoire de la Côte d'Azur, COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Ecologie Alpine (LECA ), Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Università degli Studi di Milano [Milano] (UNIMI), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), Institut de Systématique, Evolution, Biodiversité (ISYEB ), Muséum national d'Histoire naturelle (MNHN)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Matériaux et nanosciences d'Alsace (FMNGE), Institut de Chimie du CNRS (INC)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Réseau nanophotonique et optique, Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA), Université Montpellier 1 (UM1)-Institut National de la Recherche Agronomique (INRA)-Université de Montpellier (UM)-Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro), Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), Biologie et pharmacologie des plaquettes sanguines: hémostase, thrombose, transfusion, EFS-Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Strasbourg (UNISTRA)-Matériaux et nanosciences d'Alsace (FMNGE), Institut de Chimie du CNRS (INC)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-SIGMA Clermont (SIGMA Clermont)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS)-École Centrale de Lyon (ECL), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA), Department of Zoology and Entomology [Pretoria], University of Pretoria [South Africa]-University of Pretoria [South Africa], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS), Japan Aerospace Exploration Agency [Sagamihara] (JAXA), Instituto Nacional de Engenharia, Tecnologia e Inovacao (INETI), Unité d’Otologie, implants auditifs et chirurgie de la base du crâne [CHU Pitié-Salpêtrière], Service d'Oto-Rhino-Laryngologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Centre National de la Recherche Scientifique (CNRS)-Université d'Auvergne - Clermont-Ferrand I (UdA), Institut de Recherche pour le Développement (IRD)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Université Fédérale Toulouse Midi-Pyrénées-Météo-France -Institut de Recherche pour le Développement (IRD)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Météo-France -Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Institut de Recherche pour le Développement (IRD)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Université Fédérale Toulouse Midi-Pyrénées-Météo-France -Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Météo-France -Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Gaia Collaboration
- Subjects
Astrometry ,Galaxy: structure ,Parallaxes ,Proper motions ,Space vehicles: instruments ,Telescopes ,Astronomy and Astrophysics ,Space and Planetary Science ,[ PHYS ] Physics [physics] ,instruments [space vehicles] ,Physics ,FOS: Physical sciences ,[ SDU.ASTR.IM ] Sciences of the Universe [physics]/Astrophysics [astro-ph]/Instrumentation and Methods for Astrophysic [astro-ph.IM] ,telescopes ,space vehicles: instruments ,astrometry ,parallaxes ,proper motions ,[SDU.ASTR.IM]Sciences of the Universe [physics]/Astrophysics [astro-ph]/Instrumentation and Methods for Astrophysic [astro-ph.IM] ,Settore FIS/05 - Astronomia e Astrofisica ,Navigations- und Regelungssysteme ,Astrophysics - Instrumentation and Methods for Astrophysics ,Instrumentation and Methods for Astrophysics (astro-ph.IM) ,QC ,space vehicles: instruments / Galaxy: structure / astrometry / parallaxes / proper motions / telescopes ,QB ,structure [Galaxy] - Abstract
Gaia is a cornerstone mission in the science programme of the European Space Agency (ESA). The spacecraft construction was approved in 2006, following a study in which the original interferometric concept was changed to a direct-imaging approach. Both the spacecraft and the payload were built by European industry. The involvement of the scientific community focusses on data processing for which the international Gaia Data Processing and Analysis Consortium (DPAC) was selected in 2007. Gaia was launched on 19 December 2013 and arrived at its operating point, the second Lagrange point of the Sun-Earth-Moon system, a few weeks later. The commissioning of the spacecraft and payload was completed on 19 July 2014. The nominal five-year mission started with four weeks of special, ecliptic-pole scanning and subsequently transferred into full-sky scanning mode. We recall the scientific goals of Gaia and give a description of the as-built spacecraft that is currently (mid-2016) being operated to achieve these goals. We pay special attention to the payload module, the performance of which is closely related to the scientific performance of the mission. We provide a summary of the commissioning activities and findings, followed by a description of the routine operational mode. We summarise scientific performance estimates on the basis of in-orbit operations. Several intermediate Gaia data releases are planned and the data can be retrieved from the Gaia Archive, which is available through the Gaia home page at http://www.cosmos.esa.int/gaia., The Gaia Collaboration consists of 625 authors. Accepted by A&A in the Gaia Special Feature
19. Prediction of unbound carboplatin clearance from total plasma concentration to simplify dose adaptation based on therapeutic drug monitoring
- Author
-
Etienne Chatelut, Thomas, F., Paci, A., Gross-Goupil, M., Bay, J. O., Lotz, J. P., Gravis, G., Delva, R., Flechon, A., Massart, C., Gladieff, L., Marsili, S., Ciccolini, J., Lelievre, B., Guitton, J., Poinsignon, V., Chevreau, C., and Moeung, S.
20. Nonamyloidogenic TTR gene variants c.76G>A and c.337-18G>C are not associated with idiopathic small-fiber neuropathy.
- Author
-
Konecki C, Francou B, Chappell K, Augey L, Beaudonnet G, Cauquil C, Dimitri-Boulos D, Not A, Adam C, Poinsignon V, Verstuyft C, Adams D, Echaniz-Laguna A, and Labeyrie C
- Abstract
Background and Purpose: Small-fiber neuropathy (SFN) affects only unmyelinated and thin myelinated fibers. It may be caused by amyloidogenic mutations of the transthyretin (TTR) gene, but not all TTR gene variants are pathogenic. The nonamyloidogenic c.76G>A (rs1800458) and c.337-18G>C (rs36204272) variants of TTR were recently reported to be associated with SFN. We investigated this putative association by analyzing TTR gene sequencing data retrospectively for two cohorts of patients, one with SFN and a control group., Methods: In this retrospective single-center study, we analyzed the frequency of the c.76G>A and c.337-18G>C TTR gene variants in a cohort of patients meeting a strict definition of SFN, with or without dysautonomia, a control cohort of patients investigated for nonneurological conditions, and the gnomAD international database., Results: We included 55 SFN patients in this study, 17 of whom had dysautonomia. The allelic frequencies of the two variants in our cohort of 55 SFN patients were 7.27% for c.76G>A TTR and 5.25% for c.337-18G>C. The frequencies of both variants were statistically similar in the 337 control patients and the gnomAD database., Conclusions: The c.76G>A and c.337-18G>C TTR gene variants are not associated with SFN., (© 2024 The Author(s). European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.)
- Published
- 2024
- Full Text
- View/download PDF
21. Hereditary transthyretin amyloidosis in middle-aged and elderly patients with idiopathic polyneuropathy: a nationwide prospective study.
- Author
-
Fargeot G, Echaniz-Laguna A, Labeyrie C, Svahn J, Camdessanché JP, Cintas P, Chanson JB, Esselin F, Piedvache C, Verstuyft C, Genestet S, Lagrange E, Magy L, Péréon Y, Sacconi S, Signate A, Nadaj-Pakleza A, Taithe F, Viala K, Tard C, Poinsignon V, Cauquil C, Attarian S, and Adams D
- Subjects
- Male, Adult, Middle Aged, Aged, Humans, Female, Prospective Studies, Treatment Outcome, Prealbumin genetics, Amyloid Neuropathies, Familial pathology, Polyneuropathies diagnosis, Polyneuropathies genetics
- Abstract
Background: Hereditary transthyretin amyloidosis (ATTRv) is an adult-onset autosomal dominant disease resulting from TTR gene pathogenic variants. ATTRv often presents as a progressive polyneuropathy, and effective ATTRv treatments are available., Methods: In this 5 year-long (2017-2021) nationwide prospective study, we systematically analysed the TTR gene in French patients with age >50 years with a progressive idiopathic polyneuropathy., Results: 553 patients (70% males) with a mean age of 70 years were included. A TTR gene pathogenic variant was found in 15 patients (2.7%), including the Val30Met TTR variation in 10 cases. In comparison with patients with no TTR gene pathogenic variants ( n = 538), patients with TTR pathogenic variants more often presented with orthostatic hypotension (53 vs. 21%, p = .007), significant weight loss (33 vs 11%, p = .024) and rapidly deteriorating nerve conduction studies (26 vs. 8%, p = .03). ATTRv diagnosis led to amyloid cardiomyopathy diagnosis in 11 cases, ATTRv specific treatment in all cases and identification of 15 additional ATTRv cases among relatives., Conclusion: In this nationwide prospective study, we found ATTRv in 2.7% of patients with age >50 years with a progressive polyneuropathy. These results are highly important for the early identification of patients in need of disease-modifying treatments.
- Published
- 2024
- Full Text
- View/download PDF
22. Clinical and genetic features of patients suffering from CMT4J.
- Author
-
Beloribi-Djefaflia S, Morales RJ, Fatehi F, Isapof A, Servais L, Leonard-Louis S, Michaud M, Verdure P, Gidaro T, Pouget J, Poinsignon V, Bonello-Palot N, and Attarian S
- Subjects
- Adolescent, Humans, Heterozygote, Mutation genetics, Phenotype, Amyotrophic Lateral Sclerosis, Charcot-Marie-Tooth Disease diagnosis, Charcot-Marie-Tooth Disease genetics, Flavoproteins genetics, Phosphoric Monoester Hydrolases genetics
- Abstract
Mutations in the FIG4 gene have been identified in various diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and Charcot-Marie-Tooth 4 J (CMT4J), with a wide range of phenotypic manifestations. We present eight cases of CMT4J patients carrying the p.Ile41Thr mutation of FIG4. The patients were categorized according to their phenotype. Six patients had a pure CMT; whereas, two patients had a CMT associated with parkinsonism. Three patients had an early onset and exhibited more severe forms of the disease. Three others experienced symptoms in their teenage years and had milder forms. Two patients had a late onset in adulthood. Four patients showed electrophysiological evidence of conduction blocks, typically associated with acquired neuropathies. Consequently, two of them received intravenous immunoglobulin treatment without a significant objective response. Interestingly, two heterozygous patients with the same mutations exhibited contrasting phenotypes, one having a severe early-onset form and the other experiencing a slow disease progression starting at the age of 49. Notably, although 7 out of 8 patients in this study were compound heterozygous for the p.Ile41Thr mutation, only one individual was found to be homozygous for this genetic variant and exhibited an early-onset, severe form of the disease. Additionally, one patient who developed the disease in his youth was also diagnosed with hereditary neuropathy with pressure palsies. Our findings provide insights into the CMT4J subtype by reporting on eight heterogeneous patient cases and highlight the potential for misdiagnosis when conduction blocks or asymmetrical nerve conduction study results are observed in patients with FIG4 mutations., (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.)
- Published
- 2024
- Full Text
- View/download PDF
23. EGR2 gene-linked hereditary neuropathies present with a bimodal age distribution at symptoms onset.
- Author
-
Echaniz-Laguna A, Cauquil C, Chanson JB, Tard C, Guyant-Marechal L, Kuntzer T, Ion IM, Lia AS, Bouligand J, and Poinsignon V
- Subjects
- Adult, Humans, Female, Child, Male, Age Distribution, Mutation, Genotype, Phenotype, Early Growth Response Protein 2 genetics, Charcot-Marie-Tooth Disease genetics, Hereditary Sensory and Motor Neuropathy
- Abstract
Background: Mutations in the Early-Growth Response 2 (EGR2) gene cause various hereditary neuropathies, including demyelinating Charcot-Marie-Tooth (CMT) disease type 1D (CMT1D), congenital hypomyelinating neuropathy type 1 (CHN1), Déjerine-Sottas syndrome (DSS), and axonal CMT (CMT2)., Methods: In this study, we identified 14 patients with heterozygous EGR2 mutations diagnosed between 2000 and 2022., Results: Mean age was 44 years (15-70), 10 patients were female (71%), and mean disease duration was 28 years (1-56). Disease onset was before age 15 years in nine cases (64%), after age 35 years in four cases (28%), and one patient aged 26 years was asymptomatic (7%). All symptomatic patients had pes cavus and distal lower limbs weakness (100%). Distal lower limbs sensory symptoms were observed in 86% of cases, hand atrophy in 71%, and scoliosis in 21%. Nerve conduction studies showed a predominantly demyelinating sensorimotor neuropathy in all cases (100%), and five patients needed walking assistance after a mean disease duration of 50 years (47-56) (36%). Three patients were misdiagnosed as inflammatory neuropathy and treated with immunosuppressive drugs for years before diagnosis was corrected. Two patients presented with an additional neurologic disorder, including Steinert's myotonic dystrophy and spinocerebellar ataxia (14%). Eight EGR2 gene mutations were found, including four previously undescribed., Interpretation: Our findings demonstrate EGR2 gene-related hereditary neuropathies are rare and slowly progressive demyelinating neuropathies with two major clinical presentations, including a childhood-onset variant and an adult-onset variant which may mimic inflammatory neuropathy. Our study also expands the genotypic spectrum of EGR2 gene mutations., (© 2023 Peripheral Nerve Society.)
- Published
- 2023
- Full Text
- View/download PDF
24. Phenotype Presentation and Molecular Diagnostic Yield in Non-5q Spinal Muscular Atrophy.
- Author
-
Fernández-Eulate G, Theuriet J, Record CJ, Querin G, Masingue M, Leonard-Louis S, Behin A, Le Forestier N, Pegat A, Michaud M, Chanson JB, Nadaj-Pakleza A, Tard C, Bedat-Millet AL, Sole G, Spinazzi M, Salort-Campana E, Echaniz-Laguna A, Poinsignon V, Latour P, Reilly MM, Bouhour F, and Stojkovic T
- Abstract
Background and Objectives: Spinal muscular atrophy (SMA) is mainly caused by homozygous SMN1 gene deletions on 5q13. Non-5q SMA patients' series are lacking, and the diagnostic yield of next-generation sequencing (NGS) is largely unknown. The aim of this study was to describe the clinical and genetic landscape of non-5q SMA and evaluate the performance of neuropathy gene panels in these disorders., Methods: Description of patients with non-5q SMA followed in the different neuromuscular reference centers in France as well as in London, United Kingdom. Patients without a genetic diagnosis had undergone at least a neuropathy or large neuromuscular gene panel., Results: Seventy-one patients from 65 different families were included, mostly sporadic cases (60.6%). At presentation, 21 patients (29.6%) showed exclusive proximal weakness (P-SMA), 35 (49.3%) showed associated distal weakness (PD-SMA), and 15 (21.1%) a scapuloperoneal phenotype (SP-SMA). Thirty-two patients (45.1%) had a genetic diagnosis: BICD2 (n = 9), DYNC1H1 (n = 7), TRPV4 (n = 4), VCP , HSBP1 , AR (n = 2), VRK1 , DNAJB2 , MORC2 , ASAH1 , HEXB , and unexpectedly, COL6A3 (n = 1). The genetic diagnostic yield was lowest in P-SMA (6/21, 28.6%) compared with PD-SMA (16/35, 45.7%) and SP-SMA (10/15, 66.7%). An earlier disease onset and a family history of the disease or consanguinity were independent predictors of a positive genetic diagnosis. Neuropathy gene panels were performed in 59 patients with a 32.2% diagnostic yield (19/59). In 13 additional patients, a genetic diagnosis was achieved through individual gene sequencing or an alternative neuromuscular NGS., Discussion: Non-5q SMA is genetically heterogeneous, and neuropathy gene panels achieve a molecular diagnosis in one-third of the patients. The diagnostic yield can be increased by sequencing of other neuromuscular and neurometabolic genes. Nevertheless, there is an unmet need to cluster these patients to aid in the identification of new genes., Competing Interests: The authors report no relevant disclosures. Go to Neurology.org/NG for full disclosures., (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.)
- Published
- 2023
- Full Text
- View/download PDF
25. Major Depressive Disorder and Oxidative Stress: A Review of Peripheral and Genetic Biomarkers According to Clinical Characteristics and Disease Stages.
- Author
-
Ait Tayeb AEK, Poinsignon V, Chappell K, Bouligand J, Becquemont L, and Verstuyft C
- Abstract
Major depressive disorder (MDD) is currently the main cause of disability worldwide, but its pathophysiology remains largely unknown, especially given its high heterogeneity in terms of clinical phenotypes and biological characteristics. Accordingly, its management is still poor. Increasing evidence suggests that oxidative stress, measured on various matrices such as serum, plasma or erythrocytes, has a critical role in MDD. The aim of this narrative review is to identify serum, plasma and erythrocyte biomarkers of oxidative stress in MDD patients according to disease stage and clinical features. Sixty-three articles referenced on PubMed and Embase between 1 January 1991, and 31 December 2022, were included. Modifications to antioxidant enzymes (mainly glutathione peroxidase and superoxide dismutase) in MDD were highlighted. Non-enzymatic antioxidants (mainly uric acid) were decreased in depressed patients compared to healthy controls. These changes were associated with an increase in reactive oxygen species. Therefore, increased oxidative damage products (principally malondialdehyde, protein carbonyl content and 8-hydroxy-2'-deoxyguanosine) were present in MDD patients. Specific modifications could be identified according to disease stages and clinical features. Interestingly, antidepressant treatment corrected these changes. Accordingly, in patients in remission from depression, oxidative stress markers were globally normalized. This narrative review suggests the particular interest of oxidative stress biomarkers for MDD care that may contribute to the heterogeneity of the disease and provide the opportunity to find new therapeutic targets.
- Published
- 2023
- Full Text
- View/download PDF
26. The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort.
- Author
-
Poinsignon V, Colle R, Asmar KE, Mendez-David I, David DJ, Ait Tayeb AEK, Chappell K, Gressier F, Herrero H, Fève B, Becquemont L, Corruble E, and Verstuyft C
- Subjects
- Antidepressive Agents therapeutic use, Azo Compounds, Genotype, Humans, Polymorphism, Genetic, Treatment Outcome, Depressive Disorder, Major drug therapy, Depressive Disorder, Major genetics, Receptors, Serotonin, 5-HT4 therapeutic use
- Abstract
Background: Pharmacological studies have yielded valuable insights into the role of the serotonin 4 receptor (HTR4) in major depressive episodes (MDE) and response to antidepressant drugs (AD). A genetic association has been shown between HTR4 and susceptibility to mood disorders. Our study aims at assessing the association between the HTR4 genetic polymorphism, rs1345697, and improvement in depressive symptoms and remission after antidepressant treatment in MDE patients., Methods: 492 depressed patients from the METADAP cohort were treated prospectively for 6 months with ADs. The clinical outcomes according to HTR4 rs1345697 were compared after 1 (M1), 3 (M3), and 6 (M6) months of treatment. Mixed-effects logistic regression and adjusted linear models assessed the association between rs1345697 and 17-item Hamilton Depression Rating Scale (HDRS) score improvement and response/remission., Results: Over the 6 months of treatment, mixed-effects regressions showed lower improvements in HDRS scores (Coefficient=1.52; Confident Interval (CI) 95% [0.37-2.67]; p = 0.009) and lower remission rates (Odds Ratio=2.0; CI95% [1.0-4.1]; p = 0.05) in GG homozygous patients as compared to allele A carriers., Limitations: The major limitations of our study are the uncertainty of the rs1345697 effect on HTR4 function, the substantial drop-out rate, and the fact that analysis is not based on randomization between polymorphism groups., Conclusions: In our study, patients who were homozygous carriers of the variant G of the HTR4 rs1345697 had lower depressive symptoms improvement and 2-fold lower remission rates after antidepressant treatment as compared to allele A carriers. Randomization study should be done to confirm these results., (Copyright © 2021. Published by Elsevier B.V.)
- Published
- 2022
- Full Text
- View/download PDF
27. Population Pharmacokinetic Analysis of Pazopanib in Patients and Determination of Target AUC.
- Author
-
Ozbey AC, Combarel D, Poinsignon V, Lovera C, Saada E, Mir O, and Paci A
- Abstract
Pazopanib is a potent multi-targeted kinase inhibitor approved for the treatment of advanced renal cell carcinoma and soft tissue sarcoma. The pharmacokinetics of pazopanib is characterized by a significant inter- and intra-patient variability and a target through plasma concentration of 20.5 mg·L
-1 . However, routine monitoring of trough plasma concentrations at fixed hours is difficult in daily practice. Herein, we aimed to characterize the pharmacokinetic (PK) profile of pazopanib and to identify a target area under the curve (AUC) more easily extrapolated from blood samples obtained at various timings after drug intake. A population pharmacokinetic (popPK) model was constructed to analyze pazopanib PK and to estimate the pazopanib clearance of a patient regardless of the time of sampling. Data from the therapeutic drug monitoring (TDM) of patients with cancer at Institute Gustave Roussy and a clinical study (phase I/II) that evaluates the tolerance to pazopanib were used. From the individual clearance, it is then possible to obtain the patient's AUC. A target AUC for maximum efficacy and minimum side effects of 750 mg·h·L-1 was determined. The comparison of the estimated AUC with the target AUC would enable us to determine whether plasma exposure is adequate or whether it would be necessary to propose therapeutic adjustments.- Published
- 2021
- Full Text
- View/download PDF
28. Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population.
- Author
-
Barnett S, Errington J, Sludden J, Jamieson D, Poinsignon V, Paci A, and Veal GJ
- Abstract
Infants and young children represent an important but much understudied childhood cancer patient population. The pharmacokinetics and pharmacogenetics of the widely used anticancer prodrug cyclophosphamide were investigated in children <2 years of age. Concentrations of cyclophosphamide and selected metabolites were determined in patients administered cyclophosphamide at doses ranging from 100-1500 mg/m
2 (5-75 mg/kg), with various infusion times as determined by the standard treatment regimen that each patient was receiving. Polymorphisms in genes including CYP2B6 and CYP2C19 were investigated. Data generated for cyclophosphamide were analysed using a previously published population pharmacokinetic model. Cyclophosphamide pharmacokinetics was assessed in 111 samples obtained from 25 patients ranging from 4-23 months of age. The average cyclophosphamide clearance for the patients was 46.6 mL/min/m2 (ranging from 9.4-153 mL/min/m2 ), with marked inter-patient variability observed (CV 41%). No significant differences in cyclophosphamide clearance or exposure (AUC) were observed between patient groups as separated by age or body weight. However, marked differences in drug clearance and metabolism were noted between the current data in children <2 years of age and recently published results from a comparable study conducted by our group in older children, which reported significantly lower cyclophosphamide clearance values and metabolite exposures using the same population pharmacokinetic model for analysis. Whilst this study demonstrates no significant differences in cyclophosphamide clearance in patients <2 years, it highlights large differences in dosing protocols across tumour types. Furthermore, the study suggests marked differences in cyclophosphamide clearance in children less than two years of age as compared to older patients.- Published
- 2021
- Full Text
- View/download PDF
29. New dosing nomogram and population pharmacokinetic model for young and very young children receiving busulfan for hematopoietic stem cell transplantation conditioning.
- Author
-
Poinsignon V, Faivre L, Nguyen L, Neven B, Broutin S, Moshous D, Bourget P, Dufour C, Dalle JH, Galambrun C, Devictor B, Kemmel V, De Berranger E, Gandemer V, Vannier JP, Jubert C, Bondu S, Mir O, Petain A, Vassal G, and Paci A
- Subjects
- Combined Modality Therapy, Dose-Response Relationship, Drug, Drug Monitoring, Female, Follow-Up Studies, Hematologic Neoplasms pathology, Humans, Infant, Male, Myeloablative Agonists pharmacokinetics, Myeloablative Agonists therapeutic use, Prognosis, Tissue Distribution, Busulfan pharmacokinetics, Busulfan therapeutic use, Hematologic Neoplasms therapy, Hematopoietic Stem Cell Transplantation methods, Models, Statistical, Nomograms, Transplantation Conditioning
- Abstract
Background: Busulfan (Bu) is the cornerstone of conditioning regimens prior to hematopoietic stem cell transplantation, widely used in both adults and children for the treatment of malignant and nonmalignant diseases. Despite an intravenous formulation, interindividual variability (IIV) remains high and optimal exposure difficult to achieve, especially in neonates and infants., Procedure: To ensure both efficacy and safety, we set up in 2005 an observational study designed for children not fully assessed during the drug registration procedure. From a large cohort of 540 patients, we developed a Bu population pharmacokinetic model based on body weight (BW) and maturation concepts to reduce IIV and optimize exposure. A new dosing nomogram was evaluated to better fit the population pharmacokinetic model., Results: Bu clearance IIV was significantly decreased from 61.3% (covariate-free model) to 28.6% when combining BW and maturation function. Median Bu area under the curve (AUC) was 1179 µmol/L × min compared to 1025 with the EMA dosing nomogram for children <9 kg. The target AUC was reached for each BW strata, significantly increasing the percentages of patients achieving reaching the targeted AUC as compared to FDA schedule., Conclusion: This new model made it possible to propose a novel dosing nomogram that better considered children below 16 kg of BW and allowed better initial exposure as compared to existing dosing schedules. This nomogram, which would be easy to use to determine an optimal dosing schedule in daily practice, will need to be validated in clinical routine. Therapeutic drug monitoring remains strongly advisable for small children and those with specific diseases., (© 2020 Wiley Periodicals LLC.)
- Published
- 2020
- Full Text
- View/download PDF
30. Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk.
- Author
-
Pistilli B, Paci A, Ferreira AR, Di Meglio A, Poinsignon V, Bardet A, Menvielle G, Dumas A, Pinto S, Dauchy S, Fasse L, Cottu PH, Lerebours F, Coutant C, Lesur A, Tredan O, Soulie P, Vanlemmens L, Jouannaud C, Levy C, Everhard S, Arveux P, Martin AL, Dima A, Lin NU, Partridge AH, Delaloge S, Michiels S, André F, and Vaz-Luis I
- Subjects
- Adult, Antineoplastic Agents, Hormonal pharmacology, Female, Humans, Middle Aged, Prospective Studies, Tamoxifen pharmacology, Treatment Outcome, Antineoplastic Agents, Hormonal blood, Antineoplastic Agents, Hormonal therapeutic use, Breast Neoplasms drug therapy, Chemotherapy, Adjuvant methods, Medication Adherence statistics & numerical data, Tamoxifen blood, Tamoxifen therapeutic use
- Abstract
Purpose: Nonadherence to long-term treatments is often under-recognized by physicians and there is no gold standard for its assessment. In breast cancer, nonadherence to tamoxifen therapy after surgery constitutes a major obstacle to optimal outcomes. We sought to evaluate the rate of biochemical nonadherence to adjuvant tamoxifen using serum assessment and to examine its effects on short-term, distant disease-free survival (DDFS)., Patients and Methods: We studied 1,177 premenopausal women enrolled in a large prospective study (CANTO/NCT01993498). Definition of biochemical nonadherence was based on a tamoxifen serum level < 60 ng/mL, assessed 1 year after prescription. Self-reported nonadherence to tamoxifen therapy was collected at the same time through semistructured interviews. Survival analyses were conducted using an inverse probability weighted Cox proportional hazards model, using a propensity score based on age, staging, surgery, chemotherapy, and center size., Results: Serum assessment of tamoxifen identified 16.0% of patients (n = 188) below the set adherence threshold. Patient-reported rate of nonadherence was lower (12.3%). Of 188 patients who did not adhere to the tamoxifen prescription, 55% self-reported adherence to tamoxifen. After a median follow-up of 24.2 months since tamoxifen serum assessment, patients who were biochemically nonadherent had significantly shorter DDFS (for distant recurrence or death, adjusted hazard ratio, 2.31; 95% CI, 1.05 to 5.06; P = .036), with 89.5% of patients alive without distant recurrence at 3 years in the nonadherent cohort versus 95.4% in the adherent cohort., Conclusion: Therapeutic drug monitoring may be a useful method to promptly identify patients who do not take adjuvant tamoxifen as prescribed and are at risk for poorer outcomes. Targeted interventions facilitating patient adherence are needed and have the potential to improve short-term breast cancer outcomes.
- Published
- 2020
- Full Text
- View/download PDF
31. Phase I study of vinblastine in combination with nilotinib in children, adolescents, and young adults with refractory or recurrent low-grade glioma.
- Author
-
Vairy S, Le Teuff G, Bautista F, De Carli E, Bertozzi AI, Pagnier A, Fouyssac F, Nysom K, Aerts I, Leblond P, Millot F, Berger C, Canale S, Paci A, Poinsignon V, Chevance A, Ezzalfani M, Vidaud D, Di Giannatale A, Hladun-Alvaro R, Petit FM, Vassal G, Geoerger B, Le Deley MC, and Grill J
- Abstract
Background: New rescue regimens are needed for pediatric refractory/recurrent low-grade glioma. Nilotinib is a tyrosine kinase inhibitor that has potential synergistic effects with vinblastine on angiogenesis, tumor cell growth, and immunomodulation., Methods: This phase I trial aimed to determine the recommended doses of this combination for phase II trials (RP2D) using the dual-agent Bayesian continual reassessment method. Nilotinib was given orally twice daily (BID) in combination with once-weekly vinblastine injections for a maximum of 12 cycles of 28 days (clinicaltrials.gov, NCT01884922)., Results: Thirty-five pediatric patients were enrolled across 4 dose levels. The median age was 7 years and 10 had neurofibromatosis type 1. Patients had received a median of 3 prior treatment lines and 25% had received more than 4 previous treatment lines. Dose-limiting toxicity (DLT) during cycle 1 was hematologic, dermatologic, and cardiovascular. The RP2D was identified at 3 mg/m
2 weekly for vinblastine with 230 mg/m2 BID for nilotinib (estimated probability of DLT = 18%; 95% credibility interval, 7-29%). Fifteen patients completed the 12 cycles; 2 stopped therapy prematurely due to toxicity and 18 due to disease progression. Three patients achieved a partial response leading to an objective response rate of 8.8% (95% confidence interval [CI], 1.9-23.7), and the disease control rate was 85.3% (95% CI, 68.9-95.1). The 12-month progression-free survival was 37.1% (95% CI, 23.2-53.67)., Conclusions: Vinblastine and nilotinib combination was mostly limited by myelosuppression and dermatologic toxicity. The efficacy of the combination at the RP2D is currently evaluated in a randomized phase II trial comparing this regimen to vinblastine alone., (© The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.)- Published
- 2020
- Full Text
- View/download PDF
32. Estimation of Unbound Carboplatin Clearance From Total Plasma Concentrations as a Means of Facilitating Therapeutic Drug Monitoring.
- Author
-
Moeung S, Chevreau C, Poinsignon V, Guitton J, Lelièvre B, Ciccolini J, Gladieff L, Massart C, Fléchon A, Delva R, Gravis G, Lotz JP, Bay JO, Gross-Goupil M, Delahousse J, Filleron T, Lochon I, Chatelut E, and Thomas F
- Subjects
- Adult, Aged, Aged, 80 and over, Bayes Theorem, Drug Monitoring methods, Female, Humans, Linear Models, Male, Middle Aged, Prospective Studies, Young Adult, Carboplatin blood, Carboplatin pharmacokinetics
- Abstract
Background: Therapeutic drug monitoring of carboplatin is based on its unbound clearance (CLU) determined by Bayesian analysis on unbound (U) concentrations. However, the ultrafiltration of plasma samples presents technical and time constraints. Therefore, this study aims to estimate CLU using total plasma (P) concentrations., Methods: U and P concentration data of 407 patients were obtained from 2 clinical studies in which actual CLU had been determined for each patient. The patients were then split into development (277 patients) and prospective data sets (130 patients). Two approaches were evaluated. PK-model-only approach: a 3-compartment pharmacokinetic (PK) model based on U and P concentrations and taking into account the protein binding process was developed. The model with patient covariates was also evaluated. Linear regression approach: an equation (CLU = aCLP + b) was obtained by linear regression analysis between actual CLU and CLP, which is the total plasma clearance obtained by analyzing P concentrations according to a 2-compartment PK model. Predictive performance was then assessed within the prospective data set by estimating CLU from P concentrations using each approach and computing the relative percentage error (PE) between estimated CLU and actual CLU., Results: The linear regression equation was CLU (L/h) = 1.15 CLP (L/h) + 0.13. The mean PE (MPE) between CLU (estimated using the equation) and the actual CLU was +1.2% (ranging from -31% to +33%) and the mean absolute PE (MAPE) was 9.7%. With the 3-compartment PK model, the MPE was +2.3% (ranging from -41% to +31%) and the MAPE was 11.1%. Inclusion of covariates in the 3-compartment model did not improve the estimation of CLU [MPE = +6.3% (from -33% to +37%); MAPE = 11.4%]., Conclusions: The linear equation gives a relatively good estimation of CLU based on P concentrations, making PK-based carboplatin dose adaptation possible for centers without ultrafiltration facilities.
- Published
- 2019
- Full Text
- View/download PDF
33. Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations.
- Author
-
Willekens C, Renneville A, Broutin S, Saada V, Micol JB, Delahousse J, Poinsignon V, Bories C, Berthon C, Itzykson R, Boissel N, Quivoron C, Terroir-Cassou-Mounat M, Bosq J, Preudhomme C, Paci A, Penard-Lacronique V, and De Botton S
- Subjects
- Adolescent, Adult, Aged, Biomarkers, Biopsy, DNA Mutational Analysis, Female, Humans, Male, Middle Aged, Positron-Emission Tomography, Sarcoma, Myeloid diagnosis, Young Adult, Glutarates blood, Isocitrate Dehydrogenase genetics, Mutation, Sarcoma, Myeloid blood, Sarcoma, Myeloid genetics
- Published
- 2018
- Full Text
- View/download PDF
34. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
- Author
-
Loriot MA, Ciccolini J, Thomas F, Barin-Le-Guellec C, Royer B, Milano G, Picard N, Becquemont L, Verstuyft C, Narjoz C, Schmitt A, Bobin-Dubigeon C, Harle A, Paci A, Poinsignon V, Quaranta S, Evrard A, Hennart B, Broly F, Fonrose X, Lafay-Chebassier C, Wozny AS, Masskouri F, Boyer JC, and Etienne-Grimaldi MC
- Subjects
- Antimetabolites, Antineoplastic administration & dosage, Antimetabolites, Antineoplastic adverse effects, Capecitabine administration & dosage, Capecitabine adverse effects, Dihydropyrimidine Dehydrogenase Deficiency diagnosis, Dihydrouracil Dehydrogenase (NADP) analysis, Dihydrouracil Dehydrogenase (NADP) genetics, Fluorouracil administration & dosage, Fluorouracil adverse effects, France, Humans, Neoplasms drug therapy, Phenotype, Practice Guidelines as Topic, Pyrimidines administration & dosage, Pyrimidines adverse effects, Pyrimidines therapeutic use, Uracil blood, Antimetabolites, Antineoplastic therapeutic use, Capecitabine therapeutic use, Dihydropyrimidine Dehydrogenase Deficiency complications, Fluorouracil therapeutic use
- Abstract
Fluoropyrimidines (FU) are still the most prescribed anticancer drugs for the treatment of solid cancers. However, fluoropyrimidines cause severe toxicities in 10 to 40% of patients and toxic deaths in 0.2 to 0.8% of patients, resulting in a real public health problem. The main origin of FU-related toxicities is a deficiency of dihydropyrimidine dehydrogenase (DPD), the rate-limiting enzyme of 5-FU catabolism. DPD deficiency may be identified through pharmacogenetics testing including phenotyping (direct or indirect measurement of enzyme activity) or genotyping (detection of inactivating polymorphisms on the DPYD gene). Approximately 3 to 15% of patients exhibit a partial deficiency and 0.1 to 0.5% a complete DPD deficiency. Currently, there is no regulatory obligation for DPD deficiency screening in patients scheduled to receive a fluoropyrimidine-based chemotherapy. Based on the levels of evidence from the literature data and considering current French practices, the Group of Clinical Pharmacology in Oncology (GPCO)-UNICANCER and the French Network of Pharmacogenetics (RNPGx) recommend the following: (1) to screen DPD deficiency before initiating any chemotherapy containing 5-FU or capecitabine; (2) to perform DPD phenotyping by measuring plasma uracil (U) concentrations (possibly associated with dihydrouracil/U ratio), and DPYD genotyping (variants *2A, *13, p.D949V, HapB3); (3) to reduce the initial FU dose (first cycle) according to DPD status, if needed, and further, to consider increasing the dose at subsequent cycles according to treatment tolerance. In France, 17 public laboratories currently undertake routine screening of DPD deficiency., (Copyright © 2018 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
35. Ultrasound-induced mild hyperthermia improves the anticancer efficacy of both Taxol® and paclitaxel-loaded nanocapsules.
- Author
-
Boissenot T, Bordat A, Larrat B, Varna M, Chacun H, Paci A, Poinsignon V, Fattal E, and Tsapis N
- Subjects
- Animals, Antineoplastic Agents, Phytogenic pharmacokinetics, Antineoplastic Agents, Phytogenic therapeutic use, Cell Line, Tumor, Combined Modality Therapy, Female, Fluorocarbons administration & dosage, Fluorocarbons pharmacokinetics, Fluorocarbons therapeutic use, Hydrocarbons, Brominated, Mice, Nude, Nanocapsules therapeutic use, Neoplasms metabolism, Neoplasms therapy, Paclitaxel pharmacokinetics, Paclitaxel therapeutic use, Polyethylene Glycols administration & dosage, Polyethylene Glycols pharmacokinetics, Polyethylene Glycols therapeutic use, Polyglactin 910 administration & dosage, Polyglactin 910 pharmacokinetics, Polyglactin 910 therapeutic use, Tissue Distribution, Treatment Outcome, Antineoplastic Agents, Phytogenic administration & dosage, Hyperthermia, Induced, Nanocapsules administration & dosage, Paclitaxel administration & dosage, Ultrasonic Therapy
- Abstract
We study the influence of ultrasound on paclitaxel-loaded nanocapsules in vitro and in vivo. These nanocapsules possess a shell of poly(dl-lactide-co-glycolide)-poly(ethylene glycol) (PLGA-PEG) and a liquid core of perfluorooctyl bromide (PFOB). In vitro experiments show that mechanical effects such as cavitation are negligible for nanocapsules due to their small size and thick and rigid shell. As the mechanical effects were unable to increase paclitaxel delivery, we focused on the thermal effects of ultrasound in the in vivo studies. A focused ultrasound sequence was therefore optimized in vivo under magnetic resonance imaging guidance to obtain localized mild hyperthermia with high acoustic pressure. Ultrasound-induced mild hyperthermia (41-43°C) was then tested in vivo in a subcutaneous CT-26 colon cancer murine model. As hyperthermia is applied, an inhibition of tumor growth for both paclitaxel-loaded nanocapsules and the commercial formulation of paclitaxel, namely Taxol® have been observed (p<0.05). Ultrasound-induced mild hyperthermia at high acoustic pressure appears as an interesting strategy to enhance cytotoxic efficacy locally., (Copyright © 2017 Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
36. Clinical outcome of cystic fibrosis patients colonized by Scedosporium species following lung transplantation: A single-center 15-year experience.
- Author
-
Parize P, Boussaud V, Poinsignon V, Sitterlé E, Botterel F, Lefeuvre S, Guillemain R, Dannaoui E, and Billaud EM
- Subjects
- Adolescent, Adult, Antifungal Agents administration & dosage, Antifungal Agents therapeutic use, Carrier State, Female, Humans, Male, Mycoses drug therapy, Mycoses etiology, Retrospective Studies, Young Adult, Cystic Fibrosis surgery, Lung Transplantation, Mycoses microbiology, Scedosporium isolation & purification
- Abstract
Background: Fungi of the genus Scedosporium are emerging pathogens responsible for severe infections in lung transplant recipients. These infections are associated with poor prognosis and some centers consider now Scedosporium species colonization as a contraindication to lung transplantation (LT) even though no published evidence demonstrates that Scedosporium species colonization is associated with higher morbidity or mortality after LT., Methods: Here, we aim to describe characteristics and outcome of cystic fibrosis (CF) lung transplant recipients colonized with Scedosporium species in a single center over a 15-year period., Results: During the study period, 14 patients had scedosporial colonization reported. Only one patient, colonized before transplantation by Lomentospora prolificans, developed scedosporial disease. Among the eight patients colonized before transplantation by Scedosporium apiospermum complex, the median survival was 1.92 year (range 0.21-12.5). All these patients except one became free of fungal colonization after transplantation with antifungal prophylaxis including voriconazole or posaconazole. For the five patients colonized after LT, including two with L. prolificans, the median survival was 1.75 years (range 0.1-13); three of them are still alive., Conclusions: It appears to us that scedosporial colonization may not be a contraindication for LT in CF patients, as long as S. apiospermum complex is involved and a life-long azole prophylaxis prescribed., (© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
37. Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study.
- Author
-
Angevin E, Cassier PA, Italiano A, Gonçalves A, Gazzah A, Terret C, Toulmonde M, Gravis G, Varga A, Parlavecchio C, Paci A, Poinsignon V, Soria JC, Drubay D, and Hollebecque A
- Subjects
- Adult, Aged, Antimetabolites, Antineoplastic therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Deoxycytidine therapeutic use, Dose-Response Relationship, Drug, Humans, Male, Middle Aged, Protein Kinase Inhibitors administration & dosage, Proto-Oncogene Proteins c-akt antagonists & inhibitors, Ribosomal Protein S6 Kinases, 70-kDa antagonists & inhibitors, Gemcitabine, Antineoplastic Agents therapeutic use, Deoxycytidine analogs & derivatives, Neoplasms drug therapy, Protein Kinase Inhibitors therapeutic use
- Abstract
Background: LY2780301, a dual inhibitor of protein kinase B (AKT) and the downstream effector p70 ribosomal protein S6 kinase (p70S6K), may inhibit progression in tumours relying on phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signalling pathway activation. This phase IB trial investigated the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), safety, pharmacokinetics (PK) and antitumour activity of LY2780301 plus gemcitabine in patients with advanced/metastatic solid tumours., Methods: This was a non-randomised, open-label, dose escalation and dose expansion trial. Patients harbouring molecular alterations of the PI3K/AKT/mTOR pathway received once daily (QD) oral LY2780301 (400 or 500 mg) in combination with intravenous gemcitabine (750 or 1000 mg/m
2 ) on days 1, 8 and 15 of a 28-d cycle. Dose escalation followed a 3 + 3 design. Assessments included adverse events (AEs), PK and preliminary antitumour activity., Results: Fifty patients (median age, 53 years; 74% female) predominantly with mutations/amplifications of PI3K (60%) and phosphatase and tensin homologue (PTEN) gene/protein inactivation (42%) were treated for up to 14 cycles. The MTD was LY2780301 500 mg QD with gemcitabine 750 mg/m2 . DLTs during cycle 1 were grade IV thrombocytopenia, grade III skin rash and grade III increase in alkaline phosphatase, gamma glutamyltransferase and alanine aminotransferase, occurring in one patient each. Most common AEs were anaemia (84%), fatigue (84%), transaminase increase (74%), thrombocytopenia (74%), nausea/vomiting (70%), neutropenia (68%) and lymphopenia (56%). Among the efficacy-evaluable population, two patients (5%) had a partial response; the disease control rate was 74% at cycle 2., Conclusions: Addition of LY2780301 to gemcitabine showed manageable toxicity and encouraging antitumour activity in patients with molecular alterations of the PI3K/AKT/mTOR pathway., Clinical Trial Registration Number: NCT02018874., (Copyright © 2017 Elsevier Ltd. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
38. Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors.
- Author
-
Loulergue P, Merad M, Coriat R, Ducreux M, Planchard D, Boige V, Le Cesne A, Gregory TM, Poinsignon V, Paci A, and Mir O
- Subjects
- Adult, Aged, Anti-HIV Agents adverse effects, Anti-HIV Agents pharmacology, Antineoplastic Agents adverse effects, Antineoplastic Agents pharmacokinetics, Antiretroviral Therapy, Highly Active adverse effects, Drug Interactions, Female, HIV Infections metabolism, HIV Infections virology, Humans, Male, Middle Aged, Neoplasms metabolism, Neoplasms virology, Protein Kinase Inhibitors adverse effects, Protein Kinase Inhibitors pharmacokinetics, Raltegravir Potassium adverse effects, Raltegravir Potassium pharmacology, Viral Load drug effects, Anti-HIV Agents therapeutic use, Antineoplastic Agents therapeutic use, HIV Infections drug therapy, Neoplasms drug therapy, Protein Kinase Inhibitors therapeutic use, Raltegravir Potassium therapeutic use
- Abstract
Background The risk of pharmacokinetic interaction is important in HIV-infected cancer patients receiving concomitantly highly active antiretroviral therapy (HAART) and anti-cancer systemic treatments. We aimed to evaluate the safety profile of raltegravir-based HAART in cancer patients receiving multi-kinase inhibitors (MKIs). Patients and Methods We conducted a retrospective medical record review of adult, HIV-infected cancer patients treated in our institutions from January 2010 to December 2015. Patients eligible for the present analysis were those receiving a raltegravir-based HAART at the time of the initiation of a MKI for the treatment of advanced solid tumors. Treatment-related toxicity, virological outcomes and pharmacokinetic profile of MKIs were examined. Results Twelve patients (7 males, median age 55 years) were identified. Seven had sarcoma/GIST, 3 had hepatocellular carcinoma, one had pancreatic neuroendocrine tumor, and one had NSCLC. Patients received the following MKIs: imatinib (n = 3), sorafenib (n = 3), pazopanib (n = 3), sunitinib (n = 2) and erlotinib (n = 1). The mean CD4+ count at baseline was 929 cells/mm
3 , and 860 cells/mm3 after completion of MKI treatment. In all patients, HIV viral loads remained below the limit of detection (40 copies/ mm3 ) during the whole MKI treatment. No virological failure occurred. No unexpected or serious adverse event related either to raltegravir-based HAART or to MKIs was observed. The trough plasma concentrations of MKIs were assessed in 8 patients, and were found normal in all but one case (not related to raltegravir-based HAART). Conclusions The present data represent the first documentation of the concomitant use of raltegravir-containing HAART and MKIs in HIV-infected adult patients with advanced non-AIDS defining malignancies, with a reassuring safety profile.- Published
- 2017
- Full Text
- View/download PDF
39. Busulfan after HSCT in children and young adults.
- Author
-
Paci A, Poinsignon V, Broutin S, Mir O, and Vassal G
- Subjects
- Child, Cohort Studies, Humans, Retrospective Studies, Transplantation Conditioning, Young Adult, Busulfan, Hematopoietic Stem Cell Transplantation
- Published
- 2017
- Full Text
- View/download PDF
40. Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications.
- Author
-
Poinsignon V, Mercier L, Nakabayashi K, David MD, Lalli A, Penard-Lacronique V, Quivoron C, Saada V, De Botton S, Broutin S, and Paci A
- Subjects
- Biomarkers, Tumor chemistry, Biomarkers, Tumor metabolism, Cell Line, Tumor, Glutarates chemistry, Glutarates metabolism, Humans, Leukemia, Myeloid, Acute metabolism, Linear Models, Reproducibility of Results, Sensitivity and Specificity, Stereoisomerism, Biomarkers, Tumor blood, Chromatography, Liquid methods, Glutarates blood, Isocitrate Dehydrogenase metabolism, Tandem Mass Spectrometry methods
- Abstract
A recent update of the hallmarks of cancer includes metabolism with deregulating cellular energetics. Activating mutations in isocitrate dehydrogenase (IDH) metabolic enzymes leading to the abnormal accumulation of 2-hydroxyglutaric acid (2-HGA) have been described in hematologic malignancies and solid tumours. The diagnostic value of 2-HGA levels in blood to identify IDH mutations and its prognostic significance have been reported. We developed a liquid chromatography tandem mass spectrometry method allowing a rapid, accurate and precise simultaneous quantification of both L and D enantiomers of 2-HGA in blood samples from acute myeloid leukaemia (AML) patients, suitable for clinical applications. The method was also develop for preclinical applications from cellular and tissues samples. Deuterated (R,S)-2-hydroxyglutaric acid, disodium salt was used as internal standard and added to samples before a solid phase extraction on Phenomenex STRATA™-XL-A (200mg-3mL) 33μm cartridges. A derivatization step with (+)- o,o'-diacetyl-l-tartaric anhydride permitted to separate the two resulting diastereoisomers without chiral stationary phase, on a C18 column combined to a Xevo TQ-MS Waters mass spectrometer with an electrospray ionization (ESI) source. This method allows standard curves to be linear over the range 0.34-135.04μM with r(2) values>0.999 and low matrix effects (<11.7%). This method, which was validated according to current EMA guidelines, is accurate between-run (<3.1%) and within-run (<7.9%) and precise between-run (<5.3CV%) and within-run (<6.2CV%), and is suitable for clinical and preclinical applications., (Copyright © 2016 Elsevier B.V. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
41. A case of melphalan sustained accumulation in an 80-year old patient.
- Author
-
Jolivot PA, Poinsignon V, Paci A, Guidet B, Pichereau C, Fernandez C, and Hindlet P
- Subjects
- Acute Kidney Injury etiology, Acute Kidney Injury therapy, Aged, 80 and over, Anti-Infective Agents adverse effects, Antineoplastic Agents, Alkylating pharmacokinetics, Critical Care, Drug Interactions, Fatal Outcome, Female, Humans, Kidney Failure, Chronic complications, Melphalan pharmacokinetics, Multiple Myeloma complications, Multiple Myeloma drug therapy, Pneumonia, Pneumocystis complications, Pneumonia, Pneumocystis drug therapy, Trimethoprim, Sulfamethoxazole Drug Combination adverse effects, Antineoplastic Agents, Alkylating adverse effects, Melphalan adverse effects
- Abstract
Case We report the case of melphalan accumulation in an 80-year old female with multiple myeloma. Her initial health status was good except for a moderate chronic renal failure (estimated glomerular filtration rate: 31 ml/min) and anemia. Among other drugs, her usual treatment included trimethoprim/sulfamethoxazole and the patient received melphalan from day 1 to day 4 for multiple myeloma. On day 13, she was admitted in intensive care unit for acute renal failure and severe sepsis with pancytopenia. Usual treatments were stopped. Melphalan blood concentrations were 123.6 ng/ml on day 16 and 87.5 ng/ml on day 17 while cerebrospinal fluid concentration was 173.8 ng/ml on day 25. Patient recovered on day 30. Melphalan accumulation may be explained by substrate competition between sulfamethoxazole and melphalan in metabolism pathway and chronic renal failure. Conclusion close clinical and renal monitoring should be performed in patient receiving melphalan and sulfamethoxazole.
- Published
- 2015
- Full Text
- View/download PDF
42. Physico-chemical stability of busulfan in injectable solutions in various administration packages.
- Author
-
Houot M, Poinsignon V, Mercier L, Valade C, Desmaris R, Lemare F, and Paci A
- Subjects
- Chemical Phenomena, Chemical Precipitation drug effects, Drug Stability, Injections, Pharmaceutical Solutions chemistry, Pharmaceutical Solutions standards, Time Factors, Busulfan chemistry, Busulfan standards, Drug Packaging standards
- Abstract
Background and Objectives: Busulfan is used as part of a conditioning regimen prior to hematopoietic stem cell transplantation for the treatment of certain cancers and immune deficiency syndromes. Due to its instability in aqueous preparations, busulfan for infusion is prepared from a concentrate and has a relatively short shelf life once prepared. The purpose of this study was to identify the most suitable storage container and temperature to maximize the shelf life of busulfan therapeutic infusions prepared from Busilvex(®)., Methods: Busilvex(®) 6 mg/mL was diluted to 0.55 mg/mL with 0.9 % NaCl and aliquots dispensed into polypropylene syringes, polyvinyl chloride bags, and glass bottles. Three storage temperatures were evaluated: 2-8 °C, 13-15 °C (thermostatically controlled chamber), and room temperature (20 ± 5 °C). At set time points, samples were analysed for busulfan content, using a high-performance liquid chromatography (HPLC) system with ultraviolet detection. The change in pH and osmolarity on storage was also determined, and solutions were inspected visually for formation of a precipitate or colour change. To determine the contribution of precipitation to loss of busulfan content on storage, samples from one time series were treated with the solvent dimethylacetamide prior to HPLC separation and quantitation of busulfan., Results: The results of the active substance content monitoring study over a 48-h period demonstrate that busulfan solution is stable at a 5 % threshold, at 2-8 °C for 16 h in syringes, 14 h in glass bottles, and 6 h in bags. In addition, the period of stability decreases as the temperature increases (4 h at 20 ± 5 °C). The solution is considered to be stable, subject to precipitation liable to be observed regardless of the temperature., Conclusion: The best stability was observed for busulfan solutions placed at 2-8 °C in syringes. This study demonstrated that precipitation, in addition to hydrolysis, has a significant influence on the busulfan content.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.